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Microhomology-mediated end joining (MMEJ), an error-prone pathway for DNA double-
strand break (DSB) repair, is implicated in genomic rearrangement and oncogenic transformation; 
however, its contribution to repair of radiation-induced DSBs has not been characterized. We used 
recircularization of a linearized plasmid to recapitulate DSB repair via MMEJ or nonhomologous 
end-joining (NHEJ). MMEJ was significantly enhanced in irradiated cells, independent of their 
radiation-induced arrest in the G2/M phase. MMEJ activation was dependent on XRCC1 
phosphorylation by casein kinase 2 (CK2), enhancing XRCC1's interaction with the end resection 
enzymes MRE11 and CtIP. Both endonuclease and exonuclease activities of MRE11 were required 
for MMEJ. Furthermore, the XRCC1 co-immunoprecipitate complex (IP) displayed MMEJ 
activity in vitro, which was significantly elevated after irradiation. Our studies thus suggest that 
radiation-mediated enhancement of MMEJ in cells surviving radiation therapy may contribute to 
their radioresistance and could be therapeutically targeted. 
Homologous recombination (HR)-deficient cancers, especially those with mutations in 
BRCA1 or BRCA2, utilize alternative methods of DNA double-strand break (DSB) repair, in 
particular microhomology-mediated end joining (MMEJ), for repair of DSBs that arise in S/G2 
cell cycle phases as a result of replication stress. Depletion of MMEJ factors, including XRCC1, 
PARP1, and POLQ, is synthetic lethal with BRCA2 deficiency. While POLQ and PARP1 have 
been well-studied in the context of HR-deficiency, whether XRCC1 participates in MMEJ in HR-
deficient cancers is unknown. We used a variety of approaches to demonstrate XRCC1’s critical 
role in MMEJ in BRCA2-deficient cells, and discovered that XRCC1 forms an active repair 
complex with POLQ and MRE11 after replication stress that has MMEJ activity in vitro. 






replication fork restart and fork degradation in BRCA2-deficient cells. Expression of XRCC1 is 
altered in HR-deficient cancers, along with other DNA repair factors in the same region of 
chromosome 19. Collectively, these studies identify new roles for XRCC1 in HR-deficient cancers 
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1. INTRODUCTION AND SIGNIFICANCE 
1.1 Introduction to DNA repair 
1.1.1 Base Excision Repair 
 Aerobic organisms that rely on hydrolysis and oxidation to drive a variety of cellular 
processes experience endogenous oxidative DNA damage (1). DNA bases can be modified or 
lost as a result, which can lead to mutations that can cause human disease. Processes to repair 
endogenous oxidative DNA damage have evolved to maintain genomic stability and survival, 
particularly the mechanism of base excision repair (BER) (1). Most BER enzymes are highly 
conserved across species, and tight associations between BER enzyme deficiencies and mutator 
phenotypes have been established (1). BER is responsible for repairing not only oxidations, but 
alkylations, deaminations, and depurinations (1).  
Base lesions in DNA are detected by DNA glycosylases. Monofunctional glycosylases 
recognize uracil, thymine, and alkylated bases, and cleave the N-glycosyl bond between the 
sugar and the base, removing the damaged base (2). The now abasic site is recognized by the 
apurinic endonuclease APE1, which cleaves the abasic site, leaving a 3’ hydroxyl group that is a 
substrate for extension by DNA polymerase β, which can also remove the sugar using 5’ dRP 
lyase activity (2). DNA polymerase β then fills in the gap and the gap is sealed by 
XRCC1/Ligase III (2). XRCC1 stabilizes several components of the BER pathway through direct 
interactions, including Ligase III, mediating complex formation (3). On the other hand, oxidative 
DNA lesions are recognized by bifunctional glycosylases, which both excise the damaged base 
and use their AP lyase activity to cleave the phosphodiester bond of the DNA backbone, which 
leaves behind either 5’ phosphate and 3’ α, β unsaturated aldehyde (if β-elimination) or 5’ 






(3’ α, β unsaturated aldehyde) or polynucleotide kinase phosphatase (PNKP) (3’ phosphate) 
generate polymerase-compatible 3’ hydroxyl termini (2). Gap filling and ligation is then 
accomplished similarly to the monofunctional enzyme pathway. These pathways of BER are 
collectively referred to as the single-nucleotide or short-patch BER (SN/SP-BER). 
Other pathways of BER, termed long-patch BER (LP-BER), are typically engaged when 
the 5’ sugar fails to get removed by the 5’dRP lyase activity of DNA polymerase β. Instead, the 5’ 
strand is displaced extension of the 3’ strand by any of a number of different polymerases, 
including Polβ, the replicative polymerases Pol or Polλ (2). The displaced strand can be 
removed by flap endonuclease 1 (FEN1), and the nick is sealed by Ligase I. This pathway has been 
connected to DNA replication through replication factor C (RFC) and proliferating nuclear cell 
antigen (PCNA), which have been found in complex with DNA glycosylases, replicative 
polymerases, and the X-ray repair cross complementing 1 (XRCC1) scaffold (3). Precisely how 







Figure 1. Summary of base excision repair pathways and components. Reprinted from (4) with 
permission from Bentham Science Journals. 
 
1.1.2 Single-strand Break Repair 
DNA single-strand breaks (SSBs) are single-nucleotide gaps in one strand of the DNA 
duplex. These breaks often have modified 5’ and/or 3’ termini, adding to the complexity of 
repair. SSBs are generated either directly by oxidization of the sugar backbone or indirectly 
during BER after strand scission (5). Additionally, transient SSBs are frequently generated 
during transcription and replication by DNA topoisomerase 1 (TOP1) in order to relieve 






immediately religated, however, some may persist due to collision of the SSB with replication or 
transcription machinery, or with other DNA lesions. Persistent SSBs are dangerous to the cell, as 
they can lead to DNA double-strand breaks (DSBs) if they collide with replication forks, 
although replicating cells can typically repair these DSBs using homologous recombination (HR) 
(5). In post-mitotic cells, including neurons, persistence of SSBs can lead to hyperactivation of 
the DNA damage sensor poly (ADP-ribose) polymerase 1 (PARP1), which rapidly depletes 
cellular NAD+ levels and can lead to NAD+ exhaustion and cell death (5). This kind of cell 
death is characteristic of several pathological conditions that involve oxidative stress, especially 
those that occur in ischemic post-mitotic cells in the heart and brain after heart attack and stroke 
(5). 
Detection of direct SSBs is facilitated primarily by PARP1, which catalyzes addition of 
poly (ADP-ribose) (pAR) chains to itself and a number of other targets (5). This addition 
promotes the accumulation of SSBR factors at SSBs, through interaction of pAR with pAR-
binding motifs in numerous proteins, including XRCC1 (5). XRCC1 scaffolds several SSBR 
factors, stabilizing them and in some case stimulating their enzymatic activity (5). pAR chains 
are rapidly degraded by pAR glycohydrolase (PARG), which is required for efficient ligation and 
turnover of SSBR enzymes (5). Since most SSBs require some form of end processing to restore 
5’phosphate and 3’hydroxyl groups for gap filling, several different enzymes can be recruited by 
XRCC1 to accomplish end cleaning. 3’phosphate, which arises at direct SSBs induced by ROS, 
is primarily processed by PNKP. 3’phosphoglycolate, which also arises at direct SSBs induced 
by ROS, is primarily processed by APE1. 5’AMP-SSBs, which result from abortive ligation 
attempts are processed by aprataxin (APTX). TOP1-SSBs result from abortive TOP1 activity and 






PNKP, APTX, and Polβ, and has been found in complex with TDP1 and APE1, highlighting its 
role in DNA end processing (5). After end cleaning, gap filling and ligation through either short-
patch or long-patch repair pathways is completed.  
The importance of SSBR in postmitotic cells is seen in neurodegenerative diseases 
caused by mutations in TDP1 (spinocerebellar ataxia with axonal neuropathy), APTX (ataxia and 
oculomotor apraxia 1) (6) and XRCC1 (ocular motor apraxia, axonal neuropathy, and 
progressive cerebellar ataxia) (7). Additionally, PARP hyperactivation has been directly 
identified as a cause of neuronal cell death and PARP inhibitors are being investigated as therapy 
for DNA strand break repair-defective neurological disease (7). 
1.1.3 Double-strand Break Repair 
DSBs are the most deleterious form of DNA damage. They can be introduced in a 
number of ways, including by endogenous ROS, repair pathway intermediates, replication-
associated misrepair, and exogenous sources such as radiation and chemicals (8). DSBs also 
occur during immune cell development within the programmed pathways of V(D)J and class 
switch recombination (8). Persistent and misrepaired DSBs can result in cell death, senescence, 
or gross chromosomal aberrations which destabilize the genome and can drive carcinogenesis 
(9). Therefore, efficient mechanisms that quickly repair DSBs and preserve genome integrity are 
critical for cell survival and cancer avoidance. There are two major pathways of DSBR: non-
homologous end joining (NHEJ), which directly ligates a broken DNA molecule; and 
homologous recombination (HR), which uses resection, strand invasion of a sister chromatid, 
and extension using the homologous template. A minor pathway, microhomology-mediated end 








Figure 2. Pathways of single-strand break repair. Reprinted from (5) with permission from 
Nature Journals.  
 
1.1.3.1 Non-homologous end joining 
NHEJ is initiated by the recognition of broken DNA ends by the Ku70/Ku80 
heterodimer, which recruits the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to 
form the DNA-PK holoenzyme (8). The holoenzyme both bridges the broken DNA ends, 
stabilizes them, and acts as an initiator of a signaling cascade. DNA-PKcs is a member of the 
phosphatidylinositol 3-kinase-related (PIKK) family of kinases, which includes ataxia-






kinases are all critical components of the DNA damage response, and DNA-PKcs phosphorylates 
a number of substrates, including itself, other NHEJ components, and downstream effectors (8). 
One of the characteristics of NHEJ is that is does not utilize extensive homology for repair, and 
end protection by Ku prevents long-range resection. However, since DNA ends are often 
incompatible for direct ligation, limited end resection by nucleases is a necessary component of 
the NHEJ machinery. Depending on the end chemistry, several different nucleases can be 
engaged during NHEJ. Artemis is phosphorylated by DNA-PKcs and has nuclease activity at 
ssDNA-dsDNA junctions, allowing it to cut at DNA overhangs to generate blunt ends (8). 
Artemis also has 5’-> 3’ exonuclease activity on ssDNA, again removing overhangs to generate 
blunt ends (8). PNKP and aprataxin, similar to their roles in SSBR, can phosphorylate 5’ 
hydroxyl groups and remove 3’ phosphates (PNKP) or 5’AMP (aprataxin). Aprataxin and 
PNKP-like factor (APLF) and Werner (WRN) have 3’->5’ exonuclease activity (8). 
Additionally, Ku itself has 5’dRP/AP lyase activity (8). 
Gap filling by DNA polymerases may also take place during NHEJ. The family X 
polymerases (Pol β, Pol μ, Pol λ, and terminal deoxynucleotidyl transferase (TdT)) can 
participate in NHEJ, although the primary polymerases are Pol μ and Pol λ, which both have 
BRCA1 C Terminus (BRCT) domains that facilitate their interactions with Ku (8). TdT is not 
expressed in most cell types, and promotes immune diversity by adding random nucleotides to 
DSBs in T and B cells in V(D)J recombination (8). Pol μ can add nucleotides in both template-
independent and -dependent ways, whereas Pol λ is primarily template-dependent. Template-
independent activities of NHEJ polymerases are thought to be used to stabilize breaks with short 






Ligation during NHEJ happens via the XRCC4/Ligase IV complex. XRCC4 interacts with 
Ligase IV and stimulates its activity via a BRCT domain. XRCC4-like factor (XLF) helps bridge 
DNA during this process along with XRCC4 (8). 
 
Figure 3. Non-homologous end joining. Reprinted from (10) with permission from 
Nature Journals. 
 
1.1.3.2 Homologous Recombination 
Homologous recombination is initiated by extensive resection of a DSB. Initial resection 






the strand some distance away from the DSB with its endonuclease activity, which enables 
bidirectional resection (11). Mre11 resects towards the break using its 3’->5’ exonuclease 
activity, while Exonuclease 1 (EXO1) resects away from the break using its 5’->3’ exonuclease 
activity (11). Bloom (BLM) and DNA2 cooperate with MRN and Exo1 to promote long-range 
resection (12). Importantly, the choice to initiate resection is a critical point of regulation of 
DSBR pathway choice. End protection by Ku and 53BP1 promotes NHEJ, whereas MRN and 
BRCA1 promote resection and HR (13). BRCA1 plays multiple roles in HR, however, its 
primary role is thought to be the counteraction of 53BP1 at DNA ends, allowing for resection 
and subsequent HR steps (14). 
Resection generates a long stretch of 3’ ssDNA, which is coated by Replication Protein A 
(RPA) in order to protect the DNA from degradation by nucleases and formation of secondary 
structures (15). The Rad51 recombinase has to be loaded onto ssDNA in order for strand 
annealing to occur, therefore, Rad51 has to displace RPA on 3’ ssDNA. This displacement is 
facilitated by a number of accessory proteins, including BRCA2, which interacts directly with 
Rad51, and the Rad51 paralogs RAD51A, RAD51B, RAD51D, XRCC2, and XRCC3 (16). The 
other role of BRCA1 in HR is through formation of the BRCA1-PALB2-BRCA2 complex, 







Figure 4. Homologous recombination. Reprinted from (17) with permission from Annual 
Review of Cancer Biology. 
 
Rad51-coated ssDNA then invades a homologous template. Critically, this homologous 
template only exists as a sister chromatid during S/G2 phases of the cell cycle, restricting the 






template. Extension is performed primarily by Pol δ, but also by the translesions polymerases 
REV1 and Pol ζ (17). This strand invasion intermediate, called a D-loop, can be resolved in a 
number of ways. The newly synthesized strand can be displaced and can anneal across the 
original break, after which fill-in synthesis and ligation can occur, termed synthesis-dependent 
strand annealing (SDSA) (11). SDSA results in a non-crossover (NCO) event, and is the primary 
way that HR is completed in mitotic cells (11). Alternatively, double Holliday junctions (dHJs) 
can form if the second end is captured. dHJs can be resolved in a number of ways, but their 
outcome can be either NCO or crossover (CO) events (11). COs are biased towards in meiotic 
cells in order to ensure the correct segregation of chromosomes during meiosis 1 (11). COs in 
mitotic cells can lead to loss of heterozygosity (LOH) of the region distal to the CO, which can 
lead to loss of genetic information and potentially drive carcinogenesis (11). A distinct 
subpathway of HR may be engaged if a single end of a DSB engages with a homologous 
sequence but the other end does not, this is called break-induced replication (BIR) and will be 
discussed later. 
1.1.3.3 Microhomology-mediated end joining 
A backup, error-prone DSBR pathway was reported in yeast, which was able to ligate 
DSBs in the absence of Ku and Ligase IV and required short stretches of homology at the break 
site (18). NHEJ-independent pathways of DSBR have now been identified in a number of 
organisms, including humans (19). It is genetically distinct from NHEJ, HR, and another minor 
pathway, single-strand annealing (SSA) (19). We will refer to this pathway as microhomology-
mediated end joining (MMEJ). 
MMEJ is believed to be initiated by PARP1, which competes with Ku for DNA ends 






recruitment of a number of MMEJ factors, including the MRN complex (21). Initial resection of 
the 5’ end is carried out similarly to HR, by the MRN complex in cooperation with CtIP (22). 
 
Figure 5. Outcomes of HR. Reprinted from (11) with permission from Cold Spring Harbor 
Perspectives. 
 
However, long-range resection machinery, including DNA2, Exo1, and BLM, are dispensable 
for MMEJ (19). The 3’->5’ exonuclease activity of Mre11 is sensitive to other DNA ends, and is 
able to pause when complementary sequences are exposed, allowing for stabilization of DNA 
ends via microhomology (MH) alignment (23). While both the endonuclease and exonuclease 
activities of Mre11 have been reported to be required for MMEJ, it is unclear how the 
endonuclease activity of MRN is regulated during this repair process. It is also unknown how 






Once MH is exposed by resection, the DNA ends anneal and are stabilized. DNA flaps 
are trimmed by either FEN1 or CtIP, and gap filling is carried out by Pol β, Pol λ, Pol δ, or the 
translesion synthesis polymerase Pol θ (POLQ) (19). Polymerase choice by MMEJ is not well-
understood, although POLQ has been shown to have specific characteristics that make it 
compatible with MMEJ. It has a specialized helicase domain that enables displacement of RPA 
(which suppresses MMEJ) from ssDNA stretches, and contains RAD51-binding motifs that 
block HR (24-26). Additionally, POLQ can oscillate between three different modes of terminal 
transferase activity that are most efficient on 3’ overhangs, which accounts for insertions that are 
frequently observed during MMEJ (27). POLQ also has a thumb subdomain in its polymerase 
domain that enables it to grasp the primer terminus in order to extend poorly annealed termini 
and bridge DNA ends (28). Importantly, while evidence has accumulated to support POLQ as a 
key MMEJ factor, there has been no observation of interactions between POLQ and other factors 
that promote MMEJ. 
Significance evidence supports Ligase 3 as the primary MMEJ ligase. Ligase 3 
complexes with XRCC1 in cells, which is required for its stability (29). The Lig3/XRCC1 
complex physically and functionally interacts with the MRN complex in order to join duplexes 
with MH internal to breaks, resulting in deletion of the intervening segment between opposing 
MH regions (30). How these complexes interact, and whether PARP1 or the MRN complex 
directs Lig3/XRCC1 to MMEJ sites, is unknown. Ligase I has also been reported in several 
studies as acting in MMEJ (31,32). Notably, XRCC1 has also been observed to exist in complex 
with Lig1, although a direct interaction has not been demonstrated (3). How the choice of ligase 







Figure 6. Microhomology-mediated end joining. Reprinted from (19) with permission 
from Journal of Biological Chemistry. 
 
Crucially, the outcome of MMEJ is deletion of the intervening segment between MH, 
making it significantly more error-prone than NHEJ and HR (19). Insertions also commonly 
occur due to the template-independent activity of POLQ (33). Annealing can also take place with 






translocations. Generally, the mechanism of MMEJ is poorly understood, in particular its 
regulation and usage in normal cells, the roles of PARP1 and XRCC1, and its relation to 
genomic instability and cancer. 
1.2 Replication fork repair, protection, and restart 
Accurate replication of the genome is constantly challenged by DNA lesions that arise 
both from normal metabolic processes and exogenous agents. Additionally, DNA-protein 
complexes, transcription complexes, and intrinsic DNA secondary structures can act as obstacles 
to replication forks (34). DNA lesions can block polymerase procession and replicative helicases, 
replication of unrepaired DNA can result in errors, and DSBs can arise when replication forks 
stall and collapse (34). Coordination of DNA repair and replication ensures that DNA replication 
is completed with minimal errors when DNA damage is present. Both translesion synthesis and 
fork repriming can bypass lesions on ssDNA that are better repaired in the context of dsDNA 
(35). Stalled forks can be reversed, where nascent strands anneal and reverse the replisome, 
allowing for better access of repair machinery to the blocking lesion (35). Multiple replication 
origins allow for rescue of stalled forks by converging forks (35). Finally, broken and collapsed 
forks can be repaired by the homology-dependent pathways of fork repair that involve template 
switching, HR factors, break-induced replication (BIR), and microhomology-mediated BIR 
(MMBIR) (35). These pathways are coordinated with replication fork protection mechanisms, 
which prevent nascent strand degradation and promote genome stability, as well as replication 








Figure 7. Replication fork-associated damage and repair. Of particular interest are stalled, 
broken, and collapsed forks, which are repaired by fork reversal, restart, and HR/BIR/MMBIR 
pathways. Reprinted from (36) with permission from Annual Review Genetics.  
 
1.2.1 Replication fork repair 
While a number of mechanisms operate with replication in order to ensure fidelity, we 
will discuss replication fork stalling, protection, and collapse, which generates single-ended 
DSBs (seDSBs), and mechanisms of fork restart, which repair seDSBs. DSBs can arise during 
DNA replication via a number of mechanisms, including A) collision of the replisome with SSBs 






nucleases, C) cleavage of stalled forks by structure-specific endonucleases like MUS81, or D) 
collision of forks with topoisomerase-DNA complexes stabilized by topoisomerase inhibitors 
(34). While it is not well understood how seDSBs are repaired, I will go over a major pathway of 
seDSB repair, BIR and a subpathway of BIR, MMBIR. 
 
Figure 8. Sources of single-ended DSBs in mammalian cells. Reprinted from (34) with 
permission from Elsevier. 
 
The single-ended nature of these DSBs precludes repair by direct end joining and 






exposes 3’ ssDNA that can invade a homologous template and be used as a primer for extension. 
Since seDSBs are often generated by fork collapse, there is often homologous DNA nearby in 
the form of a replicating sister chromatid. Several BIR steps are similar to HR, including 
resection, RPA binding, and Rad51 displacement of RPA that facilitates homology search and 
invasion (37). However, DNA synthesis proceeds using a migrating D-loop that continuously 
displaces the newly synthesized strand (37). This mode of synthesis leads to accumulation of a 
long stretch of newly synthesized ssDNA, making it susceptible to DNA damage and 
mutagenesis (38). Synthesis continues until the end of the chromosome or until another 
replication fork is encountered. To complete repair, the newly synthesized strand is utilized as a 
template, resulting in conservative inheritance (38). Several polymerases, including Pol ε, Pol α, 
and Pol δ, take part in BIR. Pol δ is thought to be the primary polymerase taking part in leading 
strand synthesis, whereas Pol α promotes initiation of leading strand synthesis and lagging strand 
synthesis (38). In contrast to HR, BIR is highly error-prone, as more frameshift, template-
switching, and misincorporation errors take place, likely because of slippage and disassociation 
of Pol δ from the template (38).  
There are both Rad51-dependent and Rad51-independent pathways of BIR, and both 
have been best studied in yeast. The Rad51-dependent pathway requires longer stretches of 
homology, is more efficient, and requires Rad55, Rad54 and Rad57. The Rad51-independent 
pathway depends on Rad59, the Mre11-Rad50-Xrs2 complex, and on the chromatin remodeler 
complex Rdh54 Swi2/Snf2. Both pathways require Rad52. Rad51-independent BIR is thought to 
occur via Rad52-mediated annealing of small regions of homology on broken DNA ends that can 







Figure 9. Rad51-dependent break-induced replication. Reprinted from (37) with 
permission from Taylor and Francis. 
 
The preference of Rad51-independent BIR for short stretches of homology has led to the 
suggestion that it is similar to the MMBIR pathway. MMBIR is Rad51-independent, Rad52-
dependent, and contributes to segmental duplications caused by replication stress (37). This 
MMBIR, Rad51-independent pathway was also found to be engaged at telomeric breaks and at 
chromosome fragile sites (CFSs) (37). Additionally, it is thought to contribute to complex 
genomic rearrangements (CGRs) that are observed in a number of genetic neurological diseases 
(39). One type of CGR, chromoanasynthesis, is characterized by chromosomal rearrangements in 






microhomology at their breakpoints (39). Another type of CGR, chromothripsis, is common in 
cancers and involves chromosome ‘shattering’ that is reflected in a large number of 
rearrangements restricted to a single chromosome (39). Regardless of the outcome, current 
MMBIR models involve a single DNA end that anneals with microhomology repeatedly in 
different genomic regions, effectively switching template strands and resulting in a CGR.  
 
Figure 10. Schematic of microhomology-mediated break-induced replication. 
Chromosomal rearrangement outcomes are shown. Reprinted from (40) with permission from 
Cell Press. 
 
Importantly, Rad51-independent BIR/MMBIR is induced by replication stress, as 






repair which led to tandem duplications and chromosomal rearrangements (41). Similarly, 
deregulated origin licensing that leads to rereplication and replication fork collapse induced 
Rad51-independent BIR/MMBIR (42). MMBIR is also a mechanism of repair used collapsed 
replication forks at chromosomal fragile sites (CFSs), locations in the human genome that 
frequently exhibit chromosome breaks during replication stress (43).  
The limitations of current models make it difficult to distinguish between Rad51-
independent BIR and MMBIR, and whether they represent the same pathway is unknown. 
Additionally, the prevalence of DNA end-joining by NHEJ and MMEJ in mammals make 
distinguishing between BIR, MMBIR, NHEJ, and MMEJ difficult. The lack of mammalian 
systems for studying replication fork breakage and repair in order to determine the genetic 
requirements of these pathways is a major obstacle for CGR study in cancers and genetic disease. 
1.2.2 Replication fork reversal, protection, and restart 
Stabilizing stalled replication forks and restarting them efficiently is necessary for 
genome stability. A primary intermediate of restarting forks is the reversed fork, in which 
nascent DNA strands are annealed to form two important structures: 1) a four-way structure that 
resembles a Holliday junction (HJ), and 2) a seDSB. Fork reversal can promote genome stability 
in several different ways. First, by putting template strand lesions into the context of dsDNA, 
repair is promoted (35). Second, as we have gone over previously, endonuclease cleavage can 
lead to seDSB and BIR/MMBIR. Third, if the nascent strands anneal, a new primer-template 
junction is formed that can replicate past the lesion (35). And finally, a converging fork can 







Fork reversal first involves the annealing of the two nascent strands, followed by restart 
of the reversed fork. The annealing of the two nascent strands unsurprisingly requires the 
RAD51 recombinase, but also requires a DNA translocase, of which there are three, HLTF, 
SMARCAL1, and ZRANB3 (35). The contribution of these factors to fork reversal is still being 
explored, but SMARCAL1 appears to act early on in fork reversal and primarily at leading strand 
gaps, whereas HLTF is activated by lagging strand gaps (34).  
Once the reversed fork has been established, the exposed nascent strands of the fork 
typically undergo some amount of resection, in order to expose ssDNA that can either activate 
translocases to reestablish an active fork or switch templates, both of which restart replication 
(34). Unsurprisingly, the same group of nucleases that take part in resection during HR (MRE11, 
CtIP, EXO1, and DNA2) participate in resection of reversed forks (34,44). Importantly, they can 
prevent the accumulation of DSBs by promoting HR during replication. This is thought to be by 
controlled resection that enables fork restart, which has been conclusively demonstrated in the 
case of DNA2 in cooperation with the Werner (WRN) helicase (34). Exposed 3’ overhang of the 
reversed fork can be coated by RAD51, which, because of homology of the nascent strand with 
parental DNA, could facilitate annealing with sequences ahead of the fork and establishment of a 
D-loop that can restart replication. Alternatively, the 3’ overhang can be coated with RPA, which 
is recognized by the SMARCAL1 translocase, which uses an ATP motor to drive branch 
migration and reestablishment of an active fork (34). CtIP and MRE11 are known to be critical 
for fork restart, by removing Ku from seDSBs that exist at collapsed or reversed forks (45). 
Resection by MRE11 and CtIP is limited by Rad51, and more extensive resection is performed 
by EXO1 and DNA2 (44). How the extent of resection affects ssDNA coating by RPA/RAD51, 






(analogous to resection regulation in overt DSBR by MMEJ and HR) is not well-understood. 
Additionally, the coordination of resection with other factors reported to be involved in fork 
restart, including PARP1 and the helicase RECQ1, has not been well-explored. 
While controlled resection often promotes fork restart and genomic stability, extensive 
resection and degradation of stalled forks can be detrimental to cells and cause chromosomal 
aberrations. Prevention of this extensive resection is termed replication fork protection. BRCA1, 
BRCA2, and some of the Fanconi Anemia (FA) group proteins were discovered to be required 
for replication fork protection. Replication tracts that are stalled with hydroxyurea (an inhibitor 
of ribonucleotide reductase that depletes nucleotide pools) were initially observed to be degraded 
when BRCA2 was absent (46). Tracts were also degraded when Rad51-stabilization-defective 
mutant BRCA2 was present, which did not affect HR, indicating that the functions of BRCA2 in 
fork protection and HR were separable (46). The nucleases responsible for fork degradation in 
the absence of BRCA2 were found to be CtIP, MRE11 and EXO1, and degradation led to 
chromosomal aberrations (46). Similar findings were observed for BRCA1 and FANCD2 (47). 
These findings have led to a model where extensive degradation of stalled forks in BRCA-
deficient and FA-deficient cancer cells contributes to their chromosomal rearrangement 
phenotypes.   
Based on the observation that BRCA2 stabilizes Rad51 for fork protection, it is likely 
that the role of HR proteins in this pathway is in preventing the degradation of ssDNA through 
Rad51 stabilization. Since the primary source of long stretches of ssDNA at replication forks is 
after replication fork reversal, which occurs frequently at stalled forks in order to repair lesions 
that block replication, this function of BRCA2 and Rad51 was thought to be important for 






observed recently. When forks are persistently stalled, forks are reversed by the SMARCAL1 
helicase, where BRCA2 stabilizes Rad51 onto nascent ssDNA, which protects it from 
degradation by MRE11, as expected (48). Surprisingly, Rad51 exhibited an additional function, 
as it was shown to bind not only to reversed forks, but also to ssDNA gaps at replication fork 
junctions, which was promoted by BRCA2 (48). Rad51 binds directly to Pol α, and facilitates 
Pol α and δ binding to stalled forks, likely promoting fork restart and preventing fork reversal 
(48).  
BRCA1 has very recently been shown to complex with BARD1 for fork protection. The 
BRCA1-BARD1 complex interacts with RAD51, which promotes RAD51 accumulation at 
stalled replication forks (49). Genetic variants of BRCA1 and BARD1 were identified in human 
cancer patients, and were demonstrated to have defective nascent strand protection but HR 
proficiency, again separating the functions of replication fork protection from HR (49). Whether 
this pathway is distinct from BRCA2-dependent pathways of fork protection is unknown, but it 
is clear that replication fork protection by a variety of HR and FA factors is critical for genome 
stability and cancer prevention. 
Interestingly, these extensively resected forks can still restart. However, restart after 
degradation leads to chromosomal aberrations and genomic instability (46). Recent studies have 
suggested that this pathway of restart is dependent on MUS81 and POLD3 and is a 
BIR/MMBIR-like pathway (44). Interestingly, this pathway is important for fork restart in 
BRCA2-deficient cells but not BRCA1-deficient cells (44). We will discuss the connection 
between this fork degradation phenotype, mutational signatures, and the efficacy of PARP 







Figure 11. Mammalian fork protection and restart in WT and BRCA2-deficient cells. Reprinted 
from (35) with permission from Elsevier. 
 
1.3 Ionizing radiation in genome damage and repair 
Ionizing radiation (IR) is used for radiation therapy (RT), a primary method of cancer 
treatment. Close to half of all cancer patients will receive some form of RT as a part of their 
overall therapeutic plan (50,51). The main principles of RT are twofold: 1) targeting of IR to the 
tumor volume can locally induce genome damage to kill cancer cells and spare healthy tissues, 
and 2) deficiencies in DNA repair and high rates of replication sensitize cancer cells to IR, 
whereas normal cells are able to repair IR-induced damage. The effectiveness of these principles 
can be enhanced by understanding the DNA repair phenotype of an individual cancer, and 
combining RT with chemical agents that target effectors that participate in the DNA damage 






limited by the redundant nature of elements of the DDR in normal cells, whereas cancer cells 
that are deficient in one or more DNA repair pathways are unable to repair damages and die (50). 
While DNA damage is continually induced by oxidative stress, these oxidative lesions 
are distributed throughout the genome, and single lesions can be repaired with relative ease. 
Since IR involves the linear passage of energy through a cell, energy is deposited linearly when 
is passes through or nearby a DNA molecule. The proportion of DNA lesions induced by IR that 
are within a defined region of the DNA helix is therefore higher than an equal number of DNA 
lesions induced by oxidative stress. These sites of IR-induced damage localized to a small region 
of DNA are termed clustered damages, and are characteristic of IR (52). 
How much energy a given type of IR deposits within a given length is called the linear 
energy transfer (LET). X-rays and γ-rays are low-LET, whereas particle radiation is high-LET. 
Low LET IR deposits roughly 30% of its energy as clustered damages, whereas high-LET IR 
deposits around 90% of its energy as clustered damages (53). Importantly, clustered DNA 
lesions induced by IR are difficult to repair (52).  The damages induced by these types of IR is 
summarized in Table 1. 
DSBs are thought to be the most cytotoxic DNA lesion induced by IR. These DSBs are 
often complex, as they have 3’phosphoglycolate or 3’-phosphate ends, single-stranded 
overhangs, and nearby base lesions or abasic sites. Complex DSBs are also more difficult to 
repair than clean DSBs, which contributes to the effectiveness of IR in cell killing. Secondary 









IR-induced lesions in DNA Number/Gy/cell Number/Gy/cell 
γ-radiation 12C6+ ions (31.5 keV/μm) 
5,6-thymine glycol  582 372 
5-(hydroxymethyl)-2′-deoxyuridine 174 72 
5-formyl-2′-deoxyuridine 132 66 
FapyG 234 132 
8-oxo-7,8-dihydro-2′-deoxyguanosine 120 60 
SSBs 1000 
 
Table 1. Estimated quantity of DNA lesions generated by ionizing radiation. Adapted from (52) 
with permission from Elsevier. 
 
Cell killing by different forms of IR, which is termed relative biological effectiveness (RBE), is 
roughly proportional to DSB induction, which is dependent on LET. This concept of LET and 
RBE is shown in Figure 12. LET values of different types of IR is shown in Table 2. 
Type of Radiation  Energy LET (keV/μm) 
X-rays 250 kV  3 
3 MV  0.3 
Cobalt-60 1.17–133 MV  0.3 
Beta particles 10 kV  2.3 
1 MV  0.25 
Neutrons  
 
2.5 MV 20 
19 MV  7 
Protons  2 MV  16 
α-particles  5 MV  100 
Table 2. LET values for different types of ionizing radiation. Adapted from (52) with 
permission from Elsevier. 
 
While repair of individual lesions induced by IR has been well studied, repair of clustered 
DNA damage is not well understood. Mechanisms previously discussed are used to repair single 
base lesions (BER), single-strand breaks (SSBs), and DSBs (NHEJ, HR). Notably, the 
contribution of MMEJ to repair of IR-induced DNA lesions is has not been appreciated. 






application of RT and chemotherapy, as well as a variety of other areas, including space 
exploration, workplace exposures, and nuclear power plant disasters.  
 
Figure 12. Relationship between Linear Energy Transfer and Relative Biological 
Effectiveness. At peak RBE, the average distance between ionization events is roughly the 
diameter of the DNA double-helix, leading to a high number of DSBs. Reprinted from (53) with 
permission from Nature Journals. 
 
1.4 DNA repair in homologous recombination-deficient tumors 
Germline mutations in BRCA1 and BRCA2 are associated with the development of 
breast, ovarian, and other cancers (54). As discussed previously, BRCA1 and BRCA2 are both 
involved in HR and replication fork protection. HR is an error-free process, and when HR is 
defective, alternative DNA pathways are engaged to repair DSBs and restore DNA replication. 
The other modes of DSB repair, NHEJ and MMEJ, either join DNA ends directly without the use 
of sequence homology or use small stretches of homology on both sides of the break to stabilize 
an annealed intermediate, deleting the intervening sequence. Use of these alternative pathways 






increased use of error-prone pathways drives cancer initiation and progression, although diverse 
roles of BRCA1/2 in the cell could potentially be responsible for pathogenesis. 
Two groups independently described the hypersensitivity of BRCA1/2-deficient cells to 
inhibitors of the DNA damage sensor and signal transducer PARP1 (PARPi) (55,56). This 
sensitivity suggested a novel treatment strategy for HRD breast and ovarian cancers, and led to 
the testing of PARPi in clinical trials. The effectiveness of PARPi in HRD tumors was originally 
thought to be because of persistent SSBs that led to fork collapse and DSBs that could not be 
repaired via HR (57). It is now thought that PARPi prevent autoPARylation, which prevents 
PARP1 release from DNA, ‘trapping’ it (57). Trapped PARP1 is considered to be a DNA lesion, 
similar to inhibited Topoisomerase II-DNA adducts. Support for this model comes from the 
observations that PARP1-deficient cells are resistant to PARPi and that the amount of PARP1 
trapping is a better predictor of cytotoxicity in BRCA-deficient cells that inhibition of 
PARylation (57). Several different PARPi have been developed; all trap PARP1 to different 
extents.  
In vitro observations of PARPi efficacy have been strongly supported by clinical trials 
results; several PARPi - olaparib, rucaparib, and niraparib - have now been approved for cancer 
therapy in various settings (58). In controlled disease settings, olaparib was first approved in 
2014 for maintenance therapy in platinum sensitive, BRCA1/2-mutant ovarian cancers that are in 
remission after chemotherapy (58). Further investigation led to the approval of olaparib for 
maintenance therapy of ovarian cancers regardless of BRCA1/2 mutation status in 2017 (58). 
Niriparib was approved for similar indications in 2017, although the effect of progression-free 
survival was highest in BRCA1/2 mutants, intermediate in BRCA1/2 wild-type patients that had 






patients without HRD (58). Similar data was reported for rucaparib in maintenance therapy for 
ovarian cancer, which was approved in April 2018 (58). In relapsed disease settings, PARPi have 
also shown a significant clinical impact. The FDA approved olaparib in 2014 as monotherapy for 
BRCA1/2 mutant, advanced ovarian cancer (58). Rucaparib was approved for similar 
applications in 2016 (58). Talazoparib and veliparib are in late-phase trials for newly diagnosed 
advanced ovarian and other cancers (58). 
For breast cancers, olaparib has been approved for monotherapy in patients with germline 
BRCA1/2 mutant, HER2-negative, metastatic disease (58). Talazoparib has exhibited a similar 
benefit in these patients in phase III trials (58). Maintenance therapy for BRCA1/2-mutant breast 
cancer patients with olaparib is currently being tested, and clinical testing of PARPi as 
monotherapy and combination therapy in the neoadjuvant setting is also underway (58). Positive 
results have been demonstrated for veliparib with carboplatin in triple-negative breast cancers, 
although veliparib with carboplatin and paclitaxel did not show a benefit in pathological 
complete response (58). Monotherapy with talazoparib in the neoadjuvant setting has been 
promising for BRCA1/2-mutant, HER2-negative breast cancers, rationalizing targeting of these 
tumors with PARPi early in disease progression (58). 
1.4.1 Resistance to PARPi 
Importantly, chemotherapy with PARPi can lead to the acquisition of resistance to 
PARPi, like most chemotherapeutic strategies (57). There are several possible mechanisms of 
resistance that have thus far been identified. These mechanisms center around restoration of HR, 
which when functional can effectively repair trapped PARP1-DNA lesions. These can be 
mutations in BRCA1 or BRCA2 that revert the original mutation to produce a functional protein, 






PARPi (57). These mechanisms of PARPi resistance can also lead to resistance to platinum 
agents (57). An important aspect of the clinical development of PARPi applications is 
combination therapies that minimize the development of resistance and treatment plans that 
account for the similarities in mechanisms of resistance to PARPi and platinum agents. 
 
 
Figure 13. Mechanism of cell killing by PARP1 inhibition. PARP1 (i) is recruited to SSBs (ii), 
where it is activated to catalyze the addition of ADP-ribose polymers to itself and a variety of 
other substrates. Without inhibition, PARP1 auto-PARylation results in its release (vi), however, 
when PARP1 is inhibited it cannot auto-PARylate and it remains trapped on DNA. Reprinted 
from (57) with permission from Science. 
 
1.4.2 Application of PARPi 
Detection of BRCA1/BRCA2 mutations, both germline and somatic, through NGS has 
typically been used as the predictive biomarker of PARPi sensitivity, and NGS has been 






BRCA1/2 mutations on HR is not well understood, and additional breast cancer susceptibility 
genes that confer PARPi sensitivity have been identified which have uncertain effects on HR 
capacity (58). Discovery of functional biomarkers of HR and other DDR pathways that 
accurately predict PARPi sensitivity is a critical goal for proper application of PARPi (58). 
To this end, several distinct approaches have been considered, including sequencing of 
panels of PARPi-sensitivity-related genes, transcriptomic approaches, platinum sensitivity, 
immunohistochemical panels of HR proteins, and whole-genome sequencing (WGS) (58). 
Cancer genome sequencing projects, including those undertaken by Wellcome Trust Sanger 
Institute, have uncovered mutational signatures in human cancers, including a specific 
mutational signature, signature 3, that is specifically associated with BRCA1/2-mutant cancers, 
and occurs frequently in breast, ovarian, prostate, and pancreatic tumors (59). In addition to 
being associated with BRCA1/2 mutations, the signature is also associated with inactivation of 
BRCA genes through methylation, and mutations in other HR genes (60). This has led to the 
hypothesis that this signature is a more sensitive predictor of HR-deficiency, and thus PARPi 
sensitivity, than HR gene panel sequencing and other methods (61). Signature 3 includes single 
base substitutions in combination with large rearrangements that contain microhomology at their 
breakpoints, indicative of preferential use of alternative pathways for DNA repair in the absence 
of HR, likely MMEJ (59). While these mutational signatures indicate the collective use of DNA 
repair over the lifetime of the tumor, they do not indicate when these mutations take place and 
what repair pathways are active currently in the tumor. Therefore, it is possible that despite HR 
being inactivated for much of the tumor lifetime, cells with signature 3 could be HR-proficient, 






possible method of HR-deficiency diagnosis, it is likely that a combination of approaches will 
emerge as the most effective solution (58). 
1.4.3 Mutational Signature in Human Cancers 
Cancers acquire somatic mutations and copy number alterations as they progress. It is 
now clear that these mutations and structural alterations are in part due to altered DNA repair 
capacity of tumors (62). Detection of specific patterns of mutations and rearrangements can 
identify changes in DNA repair in tumors that can inform a precision medicine approach to 
cancer therapy (62). 
 
Figure 14. Mutational signatures in human cancer. A cancer’s mutational signature is a 
record of DNA damage and repair that depends on a variety of factors. Reprinted from (62) with 
permission from Nature Journals. 
 
The advent of genomic sequencing capabilities and tumor database projects have made 






features possible.  Array-based comparative genomic hybridization and single-nucleotide 
polymorphism technologies have been used to identify copy number changes, which was used to 
define initial signatures of HR-deficiency by telomeric allelic imbalances, large-scale state 
transitions, and loss of heterozygosity (LOH) (58). Currently, WGS of human tumors has made it 
possible to characterize tumors based on single-nucleotide mutations. The six possible single 
base substitutions (SBS), when placed in the context of the preceding and following bases, define 
96 possible mutations. By extracting the number of each mutation type occurring in each tumor, 
a matrix containing the distribution of mutation types in human cancers can be created. Using a 
mathematical framework termed non-negative matrix factorization (NMF), distinct mutational 
signatures that occur commonly in human cancers can be found (59). This process was initially 
performed by Alexandrov et al. in a seminal paper that identified 30 different mutational 
signatures in over 7000 cancers (59). Signature associations included age, exposures, and DNA 
repair deficiencies. Several defective DNA repair pathways have now been discovered to be 
associated with specific mutational signatures, including HR, mismatch repair (MMR), 
nucleotide excision repair (NER) and APOBEC cytosine deaminases (62). These defective DNA 
repair pathways are typically inherited familial syndromes, but can be a result of somatic 
mutations. Interestingly, this study and similar studies identified mutational signatures in 
‘atypical’ malignancies at a low frequency, indicating that germline mutations in DNA repair 
genes may predispose carriers to increased cancer rates in several different tissues, e.g non-breast 
non-ovarian cancer with BRCA1/2 mutations (63). In addition to base substitutions, signatures 
have now been updated to include the contributions of insertions, deletions, inversions, tandem 
duplications, and clustering of these structural changes (60). It is now clear that Signature 3 (HR-






tandem duplications) and 5 (deletions less than 1 MB) (60). These duplications and deletions 
have significantly elevated microhomology at their junctions, which implicates preferential 
usage of MMEJ in these tumors as an alternative to HR (60). 
1.4.4 MMEJ and HR-deficiency 
The association of Rearrangement Signatures 3 and 5 (which have microhomology at 
breakpoint junctions) with HR-deficiency raised the possibility of MMEJ taking on an increased 
role in DSBR in HR-deficient cells. Several recent papers have explored the particular 
importance of POLQ in DNA repair in HRD cancer cells. Initially, D’Andrea and colleagues 
found that POLQ expression was upregulated in epithelial ovarian cancers (EOCs) and correlated 
positively with several HR factors (24). When they depleted POLQ, HR efficiency and RAD51 
foci formation increased, and depleted cells were hypersensitive to genotoxic agents, suggesting 
POLQ both inhibits HR and contributes to genome stability in HR-proficient cells (24). They 
discovered that POLQ binds directly to RAD51 through the 847-894 amino acid region (24). 
Additionally, they showed POLQ has activity for replication stress-mediated DNA structures, 
and found that POLQ contributed to both replication progression and fork restart (24). POLQ 
expression was found to inversely correlate with HR activity, and depletion of POLQ was 
synthetically lethal in BRCA1-deficient tumor cells (24). POLQ promoted MMEJ in these 
tumors, and formed foci that were dependent of PARP1 activity (24). This work identified POLQ 
as a potential therapeutic target for HRD cancers. 
Shortly thereafter, the group of Agnel Sfeir published a study that demonstrated a role for 
POLQ in chromosomal translocations, and the absence of insertions and microhomology at 
translocations that did form in POLQ-knockout cells (26). POLQ accumulated at laser-induced 






dependent on PARP1 activity (26). POLQ was demonstrated to have a role in suppressing HR at 
telomeres in this work, by counteracting the accumulation of Rad51 foci (26). Depletion of 
POLQ in BRCA1/2-deficient cells led to the accumulation of chromosome aberrations, 
indicating that POLQ is required for genomic stability and survival of these cells (26). Sfeir 
followed up this work in 2017 by demonstrating a clear mechanism for POLQ competition with 
HR for strand break repair. They examined the effects of the helicase and polymerase domains, 
as well as the Rad51-interacting motif, on POLQ-mediated repair. The helicase and polymerase 
domains, but not the Rad51-interacting motif, were found to be necessary for survival of 
BRCA1-deficient cells (64). They also found that these domains but not the motif were required 
for translocations (64). Depletion of POLQ was also found to enhance the proportion of genome 
editing events mediated by HR (64). Then they demonstrated that the helicase domain of POLQ 
dissociates RPA from ssDNA, promoting MMEJ over HR (64). 
BRCA1/2 have also been shown to have direct roles in suppressing microhomology-
based repair pathways. BRCA2 was observed to promote HR over MMEJ and NHEJ by 
stabilizing RPA on ssDNA (65). BRCA1 was shown to suppress tandem duplications that arise 
via a replication-restart mechanism that is terminated by either canonical end-joining or MH-
mediated template switching (66). These tandem duplications occur frequently in rearrangement 
signature 3 (non-clustered rearrangements with 1-10kb tandem duplications), which is associated 
with BRCA1 deficiency. 
An unbiased CRISPR screen for DNA repair factors synthetic lethal with BRCA2 
confirmed the relationship of BRCA2 with POLQ. POLQ knockout produced the strongest 
effect, although knockout of long-patch BER and MMEJ factors also produced significant cell 






(67). Interestingly, LIG3 and POLB did not have a strong effect, indicating that XRCC1’s effect 
on survival in this context is not through its role in SSBR/BER. How exactly XRCC1 mediates 
DNA repair in HR-deficient cells is unknown and the subject of significant interest. 
These studies have collectively established suppression of microhomology-based repair 
mechanisms by HR factors, and rationalize targeting of MMEJ factors, particularly POLQ, for 
cancer therapy. Targeted integration of donor DNA via HR at CRISPR-induced DSBs has also 
been shown to benefit from POLQ depletion. To this end, several companies and scientific 
groups are developing POLQ inhibitors. However, a detailed mechanism of POLQ participation 
in MMEJ with factors other than PARP1, including XRCC1, MRE11, CtIP, and Lig1/Lig3 
remains elusive. How these factors cooperate and form repair complexes in HRD tumor cells is a 
critical question that will impact future chemotherapeutic development. 
1.5 XRCC1 in strand break repair and disease 
 While we have discussed XRCC1’s role in SSBR and MMEJ at a superficial level in 
previous sections, it is worth examining XRCC1 in more detail. After its discovery by Larry 
Thompson, XRCC1 was quickly established as a close partner of Ligase 3 and POLB, and a 
critical component of SSBR (68,69). XRCC1-deficient cells were also found to be sensitive to 
alkylating agents, UV radiation, and displayed increased levels of sister chromatid exchange 
(SCE) (70). XRCC1 knockout mice are embryonic lethal, indicating that XRCC1 is required for 
development. 
1.5.1 Structure of XRCC1 
 The human XRCC1 gene is located on chromosome 19q13.3. Human XRCC1 is a 633 
amino acid (aa) protein, composed of three conserved domains, a nuclear localization signal 






aa, the BRCT1 domain spans from 315-403 aa, and the BRCT2 domain spans from 536-633 aa. 
Two unstructured linker regions span from 183-315 aa and 403-538 aa. The XRCC1 NLS is 
located from 239-266 aa, and the PARBM is in the BRCT1 domain from 379-400 aa. The NTD 
facilitates XRCC1’s direct interaction with POLB, which is regulated by the oxidation state of 
the NTD, suggesting that redox levels in the cell can regulate SSBR at this level (71). The first 
unstructured linker domain contains an RIR-like motif that mediates a weak interaction with 
PNKP, and may facilitate an interaction with PCNA (72). The BRCT1 domain provides a surface 
for multiple protein-protein interactions, including with APE1, various DNA glycosylases, Polα-
primase, and PAR (73-75). The PARBM in this domain makes it likely that PARylation 
regulates some or all of these interactions. The second linker domain contains a forkhead-
associated (FHA) domain, which mediates interactions with APLF, APTX, and PNKP (76,77). 
Finally, the BRCT2 domain of XRCC1 mediates its strong interaction with LIG3, stabilizing 
LIG3 levels (78). XRCC1 can also homodimerize and form a heterotetramer with LIG3, 
although the biological significance of these multimers is not known (79). 
1.5.2 Post-translational modification of XRCC1 
Post-translational modifications, such as phosphorylation, ubiquitination, acetylation, and 
PARylation can regulate protein function by modulating protein-protein interactions, functional 
activity, or degradation, among others (80). XRCC1 has several serine/threonine residues that are 
possible substrates for S/T kinases, many of them in the second linker region. Reported examples 
of XRCC1 phosphorylation include phosphorylation by checkpoint kinase 2 (CHK2) on Thr284 







Figure 15. XRCC1 domain map. A) Map of XRCC1 with its domains and motifs labeled. B) 
PONDR plot of XRCC1 showing disorder in the two linker regions. C) Structural representation 
of the three domains of XRCC1. 
 
which causes dissociation of XRCC1 dimers (82), although the function of this phosphorylation 
is unknown. The most well-studied XRCC1 PTM is its phosphorylation by casein kinase 2 
(CK2) on nine residues in the second linker region, close to the BRCT2 domain. Ser518, Thr519, 
and Thr523 are the most well-studied of these residues. Phosphorylation of these residues by 
CK2 was shown to be required for interaction between XRCC1 and PNKP, APTX, and APLF, 
all of which interact with XRCC1 through its FHA domain (83-85). 
1.5.3 LIG3-independent functions of XRCC1 
A significant amount of work on XRCC1 has focused on its close connection to LIG3 
and their combined function in SSBR/BER. However, recent evidence has identified LIG3-
independent functions of XRCC1. Caldecott identified that XRCC1-dependent strand break 







Figure 16. Interactions and phosphorylation sites of XRCC1.  
XRCC1 form foci in S-phase that colocalize with Rad51, connecting it with HR (86). The 
BRCT2 domain of XRCC1 was found to be dispensable for cellular survival after treatment with 
alkylating agents (87), and similarly, LIG3-null cells are not sensitive to the same DNA-
damaging agents that XRCC1-depleted cells are sensitive to (88). This may be explained by the 
participation of XRCC1, but not LIG3, in replication-associated BER, as Hanssen-Bauer et al. 
have identified large multiprotein complexes containing XRCC1, LIG1, glycosylases, and 
elements of the replisome (3). Caldecott et al. recently found that most cellular pAR is detected 
in S phase cells during DNA replication, and that PARP activation during DNA replication 
recruits XRCC1, implicating XRCC1 in Okazaki fragment ligation, although it was not shown 
whether LIG3 participates in this process (89). Interestingly, DNA-PKcs and PARP1 were 
demonstrated to recruit XRCC1 to stalled replication forks, where it facilitated fork restart, 
although the involvement of LIG3 was not studied (90). Although it is clear that XRCC1 has 
LIG3-independent functions, those functions are still being delineated. 
1.6 Significance 
The use of microhomology in DNA repair is an important area of investigation in cancer 
biology and genetics. High levels of DNA damage in cancer cells, due to oxidative stress and 






accumulation of mutations in cancer genomes (91). These mutations can confer selective growth 
advantages on cells, which leads to their clonal expansion and an increase in proliferative 
capacity (91). In the case of chemoradiotherapy for tumors, DNA repair can lead to the clonal 
survival and the emergence of therapeutic resistance (92). Therefore, understanding DNA repair 
mechanisms is critical both for understanding tumorigenesis and the proper application of 
chemoradiotherapy. 
The error-prone nature of microhomology-mediated DNA repair mechanisms, which 
cause large deletions, insertions, and rearrangements, suggests a potentially large contribution to 
cancer evolution and therapeutic resistance (62). Indeed, recent studies have indicated that these 
mechanisms are important for cancer development and therapeutic survival (24-26). However, 
these mechanisms, and their activation in cancer cells and by ionizing radiation, are not well 
understood. 
We have focused our studies on two areas: 1) mechanisms of error-prone repair after IR 
and 2) mechanisms of error-prone repair in HR-deficient cells. The focus within each of these 
studies is on the scaffolding protein XRCC1. These studies unveil that XRCC1 has unexpected 
roles in the regulation of microhomology-mediated end joining after IR and in HR-deficient 
cancers. We hope that this knowledge will contribute to the proper application of existing 
chemoradiotherapy, and potentially aid in the development of MMEJ-targeted therapies in the 
future.  
1.7 Goals and Hypotheses 
The two major goals of this dissertation were 1) to characterize the contribution of MMEJ 
to repair of IR-induced DSBs, and 2) understand the contribution of XRCC1 to MMEJ in 






Our working hypothesis for the first project was that MMEJ contributes significantly to 
the repair of IR-induced DSBs via formation of XRCC1 repair complexes. To test this, our group 
developed a novel DSB substrate with blocked termini that could be used to distinguish MMEJ 
repair from NHEJ in cell. This substrate could also be used to measure MMEJ activity of protein 
complexes in vitro. We used these powerful techniques to characterize the impact of IR on 
MMEJ, as well as the effect of a critical post-translation modification of XRCC1 on MMEJ 
complex formation and activity. 
Our working hypothesis for the second project was that XRCC1 plays a critical role in 
BRCA2-deficient cells by mediating MMEJ. Using an isogenic set of U2OS cells, one with an 
inducible shRNA cassette targeting BRCA2, we were able to study the effect of XRCC1 depletion 
on WT and HR-deficient cells. Using a variety of cellular and in vitro techniques, we documented 


















2. METHODS AND REAGENTS* 
This section contains all the reagents and protocols employed to carry out the data in this 
dissertation. 
2.1 Buffers 
Enzymatic reactions carried out were performed using buffers supplied with purchased enzymes. 
 
2.2 Antibodies 
2.2.1 Primary Antibodies 
Mouse monoclonal ANTI-FLAG® M2-Peroxidase (HRP) antibody (A8592, Sigma), mouse 
monoclonal ANTI-FLAG® M2 antibody (F1804, Sigma), rabbit polyclonal anti-DYKDDDDK 
tag antibody (#2368, Cell Signaling Technology),  mouse monoclonal anti-6X His tag® antibody 
(ab18184, Abcam), mouse monoclonal  anti-XRCC1 antibody (#MS-434-P0, Thermo Scientific), 
rabbit polyclonal anti-phospho-XRCC1 (S518/T519/T523) antibody (A300-059A, Bethyl 
Laboratories, Inc.), rabbit polyclonal anti-PARP-1 Antibody (H-300) (sc-25780, Santa Cruz 
Biotechnology), mouse monoclonal anti-PADPR antibody (ab14459, Abcam), mouse 
monoclonal anti-DNA Ligase 3 antibody (custom made), rabbit polyclonal anti-Mre11 antibody 
(#4895, Cell Signaling Technology), rabbit polyclonal anti-CtIP antibody (ab70163, abcam),  
 
*Parts of this chapter are reprinted with permission from “Microhomology-mediated end joining 
is activated in irradiated human cells due to phosphorylation-dependent formation of the XRCC1 
repair complex” by Dutta A, Eckelmann B, Adhikari S, Ahmed KM, Sengupta S, Pandey A, et 
al., 2017. Nucleic Acids Research, 45, 2585-99, Copyright 2017 by Oxford University Press. 
Parts of this chapter are reprinted with permission from “XRCC1 promotes replication restart, 
nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells” by Eckelmann 
B, Bacolla A, Wang H, Ye Z, Guerrero EN, Jiang W, et al., 2020. Nucleic Acids Research 









1. Whole Cell Lysis 
Buffer: 
1X Tris-buffer saline (TBS) solution (50 mM Tris-HCl pH 7.5, 
150 mM  NaCl), 1% Triton X and one tablet of PierceTM 
protease inhibitor cocktail (Thermo Scientific) per 10 ml. 
2. Cytoplamic 
Extraction Buffer: 
10 mM Tris-HCl pH 7.9, 0.34 M Sucrose, 3 mM CaCl2, 2mM 
MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.1% Nonidet P-40, and 
one tablet PierceTM protease inhibitor cocktail per 10 ml. 
3. Nuclear 
Extraction Buffer: 
20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) pH 7.9, 3 mM EDTA, 10% Glycerol, 150 mM potassium 
acetate, 1.5 mM MgCl2, 1.5 mM DTT, 0.5% Nonidet P-40, and 
one tablet PierceTM protease inhibitor cocktail per 10 ml. 
4. Chromatin 
Extraction Buffer: 
150 mM HEPES pH 7.9, 1.5 mM MgCl2, 10% Glycerol, 150 
mM potassium acetate, and one tablet PierceTM protease 
inhibitor cocktail per 10 ml. 
5. FLAG Co-IP 
Wash Buffer: 
1X TBS, 0.5% Triton X 
6. 10X Annealing 
Buffer: 
100 mM Tris-HCl, pH 7.5–8.0, 500 mM NaCl, 10 mM EDTA 
7. 10X Plasmid 
Recircularization 
Assay Buffer 
20mM MgCl2, 600mM NaCl, 500mM HEPES, 20mM DTT, 10 
mM ATP, 10mM dNTP, 500 µg/ml BSA 
8. 10X CK2 Kinase 
Buffer: 
250 mM MOPS, pH 7.5, 1.5 M  NaCl, 50 mM MgCl2, 50 mM 
MnCl2, 2.5 mM DTT 
 Table 3. Buffers 
mouse monoclonal anti-Nbs1 antibody (GTX70224, Genetex), rabbit monoclonal anti-phospho-
Histone H2A.X (Ser139) (20E3) (#9718, Cell Signaling Technology), mouse monoclonal anti-
phospho-Histone H2A.X (Ser139) antibody (#05-636, EMD Millipore), mouse monoclonal anti-
β-Actin (A5316, Sigma), rabbit monoclonal anti-XRCC1 antibody (ab134056, Abcam), rabbit 
polyclonal anti-DNA polymerase Beta antibody (18003-1-AP, Proteintech), rabbit polyclonal 






antibody (D-9) (sc-6954, Santa Cruz Biotechnology), mouse monoclonal anti-BRCA2 antibody 
(2B) (OP95, EMD Millipore), mouse monoclonal anti-FEN1 antibody (B4) (sc-28355, Santa 
Cruz Biotechnology), mouse monoclonal anti-BrdU antibody (IIB5) (ab8152, Abcam), and 
mouse monoclonal anti-β-Actin (A5316, Sigma). 
2.2.2 Secondary Antibodies 
Secondary antibodies for Western Blotting were from GE Healthcare (anti-mouse, 
NA9310V; anti-rabbit, NA934V). Secondary antibodies for immunofluorescence were from 
Invitrogen (Alexa Fluor, anti-rabbit 594, A11037; anti-mouse 594, A11005; anti-rabbit 488, 
A11008; anti-mouse 488, A11001). 
2.3 siRNAs 
Target siRNA sequence (sense, antisense) (5’-3’) 
XRCC1 (ACACACACACGAUGCAUUUUU, AAAAAUGCAUCGUGUGUGUGU) 
Ligase 3 (CCACAAAAAAAAUCGAGGATT, UCCUCGAUUUUUUUUGUGGTG) 
CtIP (GCUAAAACAGGAACGAAUC, GAUUCDUUCCUDUUUUAGC) 
Ligase 1 (GGCAUGAUCCUGAAGCAGATT, UCUGCUUCAGGAUCAUGCCTT) 
Pol Q (CCUUAAGACUGUAGGUACUUU, AGUACCUACAGUCUUAAGGUU) 
FEN1 (AUCAAAGACAUACACGGGCUUGAUG, 
UCAAGCCCGUGUAUGUCUUUCAUUU) 
BRCA1 CAGCAGTTTATTACTCACTAA (target sequence) 
 
BRCA2 TTGGAGGAATATCGTAGGTAA (target sequence) 
 
ctrl MISSION siRNA Universal Negative Control #1 (Sigma) 
 
Nbs1 (CCAACUAAAUUGCCAAGUAUU, AAUACUUGGCAAUUUAGUUGG) 







2.4 Drugs and Small Molecule Inhibitors 
DNA-PK inhibitor, NU7741 (Tocris Biosciences, Bristol, UK), CK2 inhibitor, CX-4945 
(Abcam, US), Mre11 exonuclease inhibitor, Mirin (Sigma-Aldrich, US), Mre11 endonuclease 
inhibitor, PFM03 (John Tainer Lab, MD Anderson Cancer Center, Houston, TX), PARP1 
inhibitor, Rucaparib (Selleck Chemicals), ATR inhibitor, VE-821 (Sigma-Aldrich, US), 
hydroxyurea (Sigma-Aldrich, US). 
2.5 Plasmids 
 Primers for subcloning were purchased from Sigma. XRCC1WT-6XHis-pCD2E and CK2 
non-phosphorylatable mutant XRCC1CKM-6XHis-pCD2E were gifts from Keith Caldecott Lab at 
University of Sussex, UK. XRCC1 cDNA sequence was PCR amplified from XRCC1-pCDNA4 
using Platinum® Pfx DNA Polymerase (ThermoFisher Scientific) and subcloned in p3X-FLAG-
CMV14 at XbaI and ClaI restriction endonuclease sites. 
Forward primer: 5’-CCCATCGATATGCCGGAGATCCGCCTCCG-3’ 
Reverse primer: 5’-CCGTCTAGAGGCTTGCGGCACCACCCCATA-3’ 
Similarly, XRCC1CKM was subcloned similarly from XRCC1CKM-6XHis-pCD2E in p3X-
FLAG-CMV14 vector using same set of primers and identical PCR amplification protocol. 
pEGFPN1 was used as a backbone to generate linearized plasmid substrate, pNS for in cell and 
in vitro repair assays. Myc-POLQ-FLAG construct was purchased from Addgene (deposited by 
Agnel Sfeir, plasmid #731132). 
2.6 Cell culture 
U2OS cells, A549, and HEK293 cells were grown in Dulbecco's High Glucose Modified 






Healthcare Life Sciences), supplemented with 10% fetal bovine serum (Hyclone, GE Healthcare 
Life Sciences) and 1X Penicillin-Streptomycin Solution (Corning cellgro®) at 37ºC in presence 
of 5% CO2 in a CO2 incubator. Cells were washed with Dulbecco’s phosphate buffered saline 
(DPBS, Hyclone, GE Healthcare Life Sciences). Cells were trypsinized using Trypsin-EDTA 
solution (Sigma-Aldrich). Stable XRCC1-HEK293 cells were grown in DMEM selection media 
containing zeocin (Invitrogen) and G418 sulfate solution (Corning cellgro®), respectively. 
Inducible BRCA2-shRNA-expressing U2OS (B2) and inducible scrambled-shRNA-expressing 
U2OS (scr) cell lines were a gift from Ryan Jensen (Yale University). They were cultured in 2 
μg/ml puromycin (Invivogen), and shRNA expression was induced with 10μg/ml doxycycline 
for 72 hrs. U2OS-EJ2 cells were a gift from Jeremy Stark (City of Hope). They were cultured in 
2 μg/ml puromycin (Invivogen). 
2.7 Irradiation 
The cells were irradiated with an RS2000 (Rad Source Technologies, Inc., Suwanee, GA)  
160 kVp X-ray source. Tissue culture plates or chamber slides containing cells were placed in shelf 
3, circle 4, where the dose rate is 2.0 Gy/min and the uniformity of dose across the field in 
horizontal plane is >95%. After irradiation the plates or slides were immediately returned to their 
incubators. 
2.8 Recombinant proteins 
Recombinant XRCC1, Mre11, XRCC1 domains, Mre11 domains, DNA Ligase 3α and 
XRCC1/DNA ligase 3α complex were purified by Pavana Dixit at Mitra Lab from cell pellets 









2.9 Protein extraction 
2.9.1 Whole cell lysis 
Cells were washed with DPBS and harvested with a cell scraper. The cells were pelleted 
at 800 rpm, 4ºC for 5 min and lysed with whole cell lysis buffer (500 µl per 10 cm plate) by 
vortexing for 15 min and centrifuged at 14000 rpm, 4ºC for 15 min, after which the supernatant 
was retrieved. 
 
2.9.2 Nuclear fraction isolation 
After pelleting, cells were resuspended in cytoplasmic extraction buffer (500 µl per 10 
cm plate) and mixed by pipetting 10-15 times. The suspension was briefly vortexed and 
centrifuged at 3500 g. Supernatant (cytoplasmic fraction) was discarded. The nuclear pellet was 
resuspended in whole cell lysis buffer (300 µl per 10 cm plate), centrifuged at 14000 rpm, 4ºC for 
15 min, after which the supernatant was retrieved. 
 
2.10 Co-immunoprecipitation 
Protein concentration of whole cell lysates from appropriate cells were measured 
through Bio-rad protein assay. ANTI-FLAG® M2 affinity gel beads (Sigma-Aldrich) were washed 
with cold 1X TBS buffer and mixed with whole cell lysate (10 µl per 1 mg of total protein). The 
volume was adjusted with 1X TBS to keep the final concentration of Triton-X 0.5%. The beads 
were incubated 3 hrs at cold room to carry out the co-IP. The beads were washed with FLAG co-
IP wash buffer 3 times for 5 min each. The beads were eluted with 2X LDS dye and heated for 1 










2.11 Protein transfer and Western Blotting 
Protein or co-IP samples were loaded along with Precision Plus Protein™ Dual Color 
Standards (Bio-rad) in NuPAGE Novex 4-12% Bis-Tris Protein Gels (Invitrogen) or Criterion™ 
XT Bis-Tris gels (Bio-rad), and gel electrophoresis was carried out in 1X NuPAGE running buffer 
(Invitrogen) or MOPS-XT buffer (Bio-rad), respectively. Protein transfer from SDS-PAGE gels to 
nitrocellulose membrane (Invitrogen) were carried out in 1X NuPAGE transfer buffer (Invitrogen) 
or 1X Tris-Glycine transfer buffer (Invitrogen) respectively. After transfer, nitrocellulose 
membranes were blocked with 5% skim milk (Fisher Scientific) solution in 1% Tris-Buffered 
Saline and Tween 20 (TBST) buffer (Invitrogen). This was followed by blotting with appropriate 
primary and secondary antibodies. Washing was done with 1% TBST. 
 
2.12 Immunofluorescence 
U2OS/A549 cells were grown in 8 chamber slides and after appropriate treatment, they 
were fixed with 4% paraformaldehyde for 15 min, followed by permeabilization with 0.5% Triton-
X solution in DPBS for 15 min. Blocking was performed with 3% BSA solution in DPBS with 
0.2% Triton-X for 1 hour. The samples were incubated overnight with appropriate primary 
antibodies diluted in DPBS with 0.2% Triton-X. Cells were then washed 3X with DPBS with 0.2% 
Triton-X and incubated with conjugated secondary antibody for 1 hr. Cells were again washed 3X 
with DPBS with 0.2% Triton-X after which the slides were air-dried. The slides were mounted 
with mounting media with DAPI (Duolink) and coverslip. The samples were observed under 60X 
oil-immersion lens in Nikon upright bright-field/fluorescent microscope or inverted Zeiss 
microscope and images were captured from five random fields for each sample. The images were 









2.13 Proximity Ligation Assay 
Proximity ligation assay (PLA) is an immunochemistry-based technique for detecting in 
situ protein-protein interaction or co-localization. For each assay, two primary antibodies raised in 
different species were used. PLA was performed with the Duolink kit (Olink Bioscience) following 
the manufacturer’s protocol using buffers and reagents provided in the kit. U2OS/HEK293 cells 
grown in 8 chamber slides with appropriate treatment were fixed with 4% paraformaldehyde and 
permeabilized with 0.5% Triton-X solution in DPBS. The cells were blocked with blocking 
solution (Duolink) for 30 mins at 37ºC in a CO2 incubator. Appropriate primary antibodies were 
diluted in Antibody Diluent Solution (Duolink) and added to the wells and incubated overnight at 
4ºC. Then, wells were washed 2X with PLA Wash Buffer A (Duolink) for 5 min. The samples 
were incubated with Duolink plus and minus probes diluted appropriately in Antibody Diluent 
Solution and incubated for 1 hr at 37ºC in a CO2 incubator. The samples were again washed 2X 
with Wash Buffer A and ligation was carried out by incubating the samples with 0.3 µl Ligase per 
well diluted in 30 µl 1X Ligation Stock (Duolink) for 30 mins at 37ºC in a CO2 incubator. The 
samples were again washed and Amplification was carried out by addition 0.2 µl Polymerase 
diluted in 30 µl 1X Amplification Stock (Duolink) and incubating 2 hrs at 37ºC in a CO2 incubator. 
Amplification step was carried out in the dark and slides were protected from light thereafter. 
Finally, slides were washed with Wash Buffer B (Duolink) 2X for 10 min and 1X with 0.01X 
Wash Buffer B for 1 min. The slides were air dried and mounted with mounting media with DAPI 
(Duolink) and coverslip. The slides were observed under 60X oil-immersion lens in Nikon upright 
bright-field/fluorescent microscope or inverted Zeiss microscope and images were captured from 







Figure 17. Cartoon depicting Proximity Ligation Assay (Sigma-Aldrich, Duolink PLA). 
Reprinted with permission from Sigma-Aldrich. 
 
2.14 In Cell Plasmid Recircularization Assay 
100 ng of the repair substrate, pNS was transfected in exponentially growing control or 
appropriately treated U2OS/A549 cells using Lipofectamine 2000 and incubated overnight. Next 
day the cells were checked for GFP expression and plasmids were isolated using Qiagen plasmid 
miniprep kit. 5 μl of plasmid extract was transfected in XL10-gold ultracompetent cells using 
manufacturer’s protocol and plated in 50 µg/ml Kanamycin containing LB-agar plates. The 
bacterial plates were sent to GENEWIZ (South Plainfield, NJ) for sequencing of randomly 
chosen 40 colonies using CMV-F primer. Relative percentage of repaired joints by MMEJ or 
NHEJ was plotted and statistical analysis was performed by two-tailed Fisher’s exact t test using 
Prism software. 
2.15 In Vitro Plasmid Recircularization Assay 
Exponentially growing U2OS cells transiently expressing XRCC1-FLAG were treated 
with drugs/inhibitors/siRNAs as indicated and/or irradiated with 3 Gy X-rays. After 1 hour, the 






performed by incubating 1.5 mg of nuclear extract with FLAG-M2 agarose beads for 2 h at 4°C. 
The beads were directly incubated 30 mins with 5ng pNS in a reaction buffer containing 2mM 
MgCl2, 60mM NaCl, 50mM HEPES, 2mM DTT, 1 mM ATP, 1mM dNTP and 50 µg/ml BSA 
under mild shaking. This was followed by addition of 14 ng XRCC1-DNA ligase 3α 
recombinant protein complex in the reaction mix and incubation overnight at 16°C. The beads 
were spun down and 5 μl of the reaction mix was transformed in XL10-gold ultracompetent cells 
and sequence analysis of colonies were performed as discussed earlier. Number of colonies 
obtained from each experiment was plotted and statistical analysis was performed by two-tailed 
Fisher’s extact t test using Prism software. The beads were eluted with 2X LDS loading buffer 
and analyzed by western blotting. 
2.16 γH2AX Foci Formation Assay 
U2OS cells with appropriate siRNA treatment were plated in 8-chamber slides and 
incubated overnight. Next day the cells were treated with appropriate drugs (hydroxyurea for 3h), 
or inhibitors (NU7441 for 1hr, Rucaparib and CX4945 for 2 hr) prior to X-ray irradiation. After 1 
hour incubation the cells were fixed with 4% paraformaldehyde for 15 minutes, followed by 
permeabilization with 0.5% Triton-X solution in DPBS for 15 min. Blocking was performed with 
3% BSA solution in DPBS for 1 hour. The samples were incubated with anti-phospho-serine 
H2A.X antibody diluted 1:500 in DPBS with 0.2% Triton-X for 2 hrs at room temperature. After 
washing 3X with DPBS with 0.2% Triton-X, the cells were incubated with conjugated secondary 
antibody (1:500). After washing, the slides were dried for 5-10 mins in a 37°C incubator and 
mounted with mounting media containing DAPI (Duolink) and coverslips. The samples were 
observed under 60X oil-immersion lens in Nikon upright bright-field/fluorescent or an inverted 






were merged and foci were counted through ImageJ software. Mean number of γH2AX foci per 
cell were plotted. 
2.17 Clonogenic Assay 
U2OS cells were transfected with 100nM control siRNA or XRCC1 siRNA and incubated 
72 hrs. Cells were treated with 10 μM NU7441/ DMSO for 1hr, and thereafter exposed to different 
dose of X-rays (0, 3, 6, 9 Gy). Or cells were treated with hydroxyurea (3 mM) or VE-821 (ATRi) 
(3 μM) for 8 hr. The cells were trypsinized and 300 cells from each sample were plated in 
quadruplicate in 6 well plates. The NU7441 pre-treated cells were replated in DMEM containing 
10μM NU7441. After 10 days the plates were harvested and the colonies were stained with 0.5% 
crystal violet solution in 50/50 methanol/water for 15 mins. The plates were washed gently in 
water and air-dried for counting the colonies. 
2.18 EJ2 Assay and Flow Cytometry 
 For EJ2-MMEJ assay, we followed Jeremy Stark’s published protocols for cell treatment, 
depeletion with siRNA, DSB induction by ISceI transfection, and cell harvesting. Flow 
cytometry was performed using a BD FACS LSRII with assistance from David Haviland and 
data were analyzed using Flowing Software (Perttu Terho, Turku Centre for Biotechnology). 
2.19 Comet Assay 
Neutral comet assay was performed using the Trevigen CometAssay Kit (4250-050-K) 
according to manufacturer’s protocol. At least 50 random comets for each sample were analyzed 
using CaspLab software. 
2.20 Single-Strand Nick Ligation Assay 
Annealed oligomers, one containing a nick, labeled with Cy3 fluorescent dye were mixed 






30°C for 20 min, followed by incubating with 2x TBE sample buffer at 100°C for 3 min and on 
ice for another 3 min. Oligomers were separated by denaturing urea polyacrylamide gel 
electrophoresis, and Cy3 fluorescence was detected by a Typhoon FLA 7000 system. 
2.21 DNA Fiber Analysis 
Cells were labeled with 50 μM CldU (Sigma), exposed to hydroxyurea (4 mM), and 
labeled with 50 μM IdU (Sigma) as indicated in the figures. DNA fibers were spread as 
described by Jackson and Pombo, and fiber tracts were detected using anti-IdU (BD Biosciences, 
347580) and anti-CldU (Novus Biologicals, NB500-169) primary antibodies and Alexa Fluor 
488 and 555 secondary antibodies (Invitrogen). Fibers were imaged at 60x magnification with oil 
immersion using a Zeiss microscope and analyzed with ImageJ.  
2.22 Statistical Analyses 
All statistics were performed using Prism software. Fiber assay distributions were 
analyzed using the Mann-Whitney U test. PLA foci distributions, comet assay distributions, 
MMEJ in vitro assay, EJ2 repair events, and clonogenic survival assay were analyzed using 














3. MICROHOMOLOGY-MEDIATED END JOINING IS ACTIVATED IN 
IRRADIATED HUMAN CELLS DUE TO PHOSPHORYLATION-DEPENDENT 
FORMATION OF THE XRCC1 REPAIR COMPLEX* 
3.1 Introduction 
About half of all cancer patients are treated with IR, either alone or in combination with 
surgery and/or chemotherapy (50). However, invariable development of resistance to 
radiotherapy in recurrent cancers warrants comprehensive understanding of the repair of IR-
induced DNA damage, which promotes tumor cell survival. IR induces clustered damage in the 
genome, including highly cytotoxic DSBs, together with an excess of closely spaced SSBs, AP 
sites and oxidized bases (93). In dividing cells, DSBs can be repaired accurately in the S/G2 
phase via HR, which requires resection at the 5’ DSB termini to generate 3’ overhangs, followed 
by invasion of the homologous sequence in the undamaged sister chromatid (94). However, 
NHEJ, which involves ligation of blunt ends, is the predominant pathway for DSBR, 
independent of cell cycle phase (8). Although NHEJ can be error-prone at complex DSBs (95) as 
a result of end resection and/or gap filling prior to ligation (96), the binding of Ku limits end 
resection at DSB ends, preventing significant loss of nucleotides (97). A recently characterized, 
highly error-prone DSBR process variously named backup NHEJ, alternative NHEJ, or 
alternative end joining (Alt-EJ), does not require NHEJ proteins but utilizes the BER/SSBR 
proteins including PARP1, XRCC1, and LIG1/LIG3 for joining the DSB termini (30,98,99). 
Significant diversity in Alt-EJ has been observed, with several sub-pathways differing in their 
 
*Parts of this chapter are reprinted with permission from “Microhomology-mediated end joining 
is activated in irradiated human cells due to phosphorylation-dependent formation of the XRCC1 
repair complex” by Dutta A, Eckelmann B, Adhikari S, Ahmed KM, Sengupta S, Pandey A, et 






requirement for preexisting or de novo microhomology (100), while a few reports have described 
microhomology-independent processes for Alt-EJ (101,102).  
MMEJ carries out DSB joining via annealing of short microhomology sequences (5–25 
bases) to the complementary strand spanning the break site (100). The consensus requirement for 
MMEJ is the initial resection of DSB ends by MRE11/RAD50/NBS1 (MRN) and CtIP, 
analogous to that observed in HR, in order to generate a 3’ ssDNA overhang that helps search for 
microhomology sequences across the DSB (103). After annealing of the microhomology 
sequences, any resulting flap segments are removed by the endonuclease activity of CtIP or flap 
endonuclease 1 (FEN-1), followed by gap-filling in both strands by a DNA polymerase, such as 
DNA polymerase θ or λ, and finally ligation of the nicks by LIG1/3 (104). However, how these 
steps are regulated is not understood. In any event, MMEJ results in loss of one microhomology 
sequence and the intervening region, which leads to deletions of variable size. MMEJ, active in 
both normal and cancer cells (98), could serve as a backup pathway to NHEJ (105). However, 
recent studies have suggested that it could be a dedicated pathway in cancer cells, particularly 
those with deficiencies in HR activity (24,106). Whole-genome sequence data from large cohorts 
of cancer patients has suggested a significant contribution of MMEJ to the genomic instability in 
cancer cells, via deletion, insertion, inversion, and complex structural changes (107,108).  
In the present study, we investigated the contribution of MMEJ to repair of IR-induced 
DSBs. Strand breaks generated by IR have non-ligatable termini containing 3’ phosphate (P) 
and/or 3’ phosphoglycolate (109), which need to be removed to generate the 3’ OH terminus 
required for repair synthesis and ligation. Incidentally, the proportion of 3’ P termini at IR-
induced strand breaks in synthetic oligonucleotides increases under hypoxic and anoxic 






we developed an in cell assay based on circularization of a linearized GFP reporter plasmid 
containing 3’ P termini, followed by sequence analysis of the repaired joints. After documenting 
that in cell circularization of this novel substrate recapitulated the requirements for NHEJ and 
MMEJ in the cellular genome, we observed that MMEJ activity is low relative to NHEJ in 
untreated cells, as expected. However, MMEJ activity was significantly enhanced after radiation 
treatment. We then focused on the scaffold protein XRCC1, which interacts with both SSBR 
proteins and MRN, all of which are recruited at IR-induced clustered damage sites. We tested the 
hypothesis that XRCC1, via phosphorylation by CK2, forms a repair-competent complex to carry 
out MMEJ. Finally, our observation that the XRCC1-IP can perform MMEJ in vitro, similar to 
what our group observed previously with BER complexes (111), could allow us to identify 
undiscovered factors involved in MMEJ. 
3.2 Results 
3.2.1 In Cell Plasmid Recircularization Assay 
The mechanisms of DSBR in the mammalian genome are commonly investigated 
through generation of site-specific DSBs by an ectopic meganuclease such as I-SceI (112). 
Although this strategy can quantitatively characterize HDR versus NHEJ at specific genomic 
loci, the induced DSBs do not resemble the complex strand breaks induced by ionizing radiation, 
which include SSBs, oxidized bases, and DSBs with non-ligatable termini (52). To explore how 
radiation-induced DSBs are repaired in the genome, we used circularization of a reporter 
plasmid, linearized with nonligatable 3’P termini, as a model system for analyzing DSB repair 
via NHEJ or MMEJ. We followed the repair, i.e. circularization of the linearized GFP reporter 
plasmid, pNS, in transfected human cells from which the plasmid population was recovered and 






resistant colonies based on expression of the drug resistance gene in the plasmid (pEGFPN1). 
Noncircularized plasmid molecules recovered from the human cells could not be circularized in 
E. coli because these are promptly degraded by the RecB/C nuclease. Linearized plasmid was 
shown to have > 103-fold lower transformation efficiency than the circular plasmid in wild-type 
E. coli used in our experiments. To ensure that we eliminated any chance of recovering drug 
resistant E.coli colonies resulting from plasmid recircularization in the E. coli, we treated the 
plasmid extracted from transfected human cells with lambda exonuclease (NEB) to remove any 
linear plasmids. We observed no significant difference in the transformation efficiency or in the 
relative products of NHEJ versus MMEJ in untreated vs. lambda exonuclease-treated plasmid 
extracts, as we had expected. Finally, DSB repair via HDR was precluded because the plasmids 
lack the ability to replicate in human cells. Thus, each bacterial colony represented an individual 
DSB repair event in the human cell. Subsequent sequence analysis of the rejoined region in 
individual plasmids allowed us to evaluate the relative contribution of NHEJ and MMEJ to the 
repair of the DSB in pNS. In order to quantitate the relative contribution of MMEJ versus NHEJ, 
we introduced a pair of 5 nt long microhomology sequences flanking the DSB, following the 
current consensus on the requirement for MMEJ, as has been characterized by both in vitro and 
chromatin-based DSB repair assays in human and yeast cells (98,113,114).  
We transfected human osteosarcoma U2OS cells or human lung carcinoma A549 cells at 
70–80% confluency with linearized pNS, which expresses GFP only if circularized via DSB 
repair (end joining). Although GFP expression was observed as early as 6 h after transfection, we 
routinely harvested cells after overnight incubation (15 h) of the transfected cells before 
extracting the plasmid for transforming E. coli. At least 40 kanamycin-resistant colonies were 






and 3’OH, generated either by removal of the 3’P termini by PNKP (115), exonucleolytic 
degradation of a few terminal bases, or gap-filling synthesis, which leads to either error-free 
repair or that with a small deletion/insertion. On the other hand, MMEJ of our plasmid substrate  
 
Figure 18. Schematic representing in cell repair of pNS to quantify MMEJ vs. NHEJ. Reprinted 
from (156) with permission from Oxford University Press. 
 
would involve annealing at the microhomology sequence, resulting in a larger deletion with the 
loss of one microhomology sequence. We observed long non-specific deletions (>10 nt) in a 
small number of plasmid molecules, which were ignored because of their likely formation due to 
non-specific exo/endonucleolytic degradation at the DSB termini. Thus, the molecules with only 
a 1–3 nt insertion or 1–10 nt deletion were scored as products of NHEJ, while those with a 
deletion of one microhomology sequence (including the intervening sequence) were counted as 







Figure 19.  pNS sequence details. (A) Sequence of pNS. (B) Modes of NHEJ. (C) Modes 
of MMEJ. (D) Sequencing outcomes of repair. Reprinted from (156) with permission from 
Oxford University Press. 
 
contributor to repair of pNS in both U2OS and A549 cells, while a small fraction of repair events 






general agreement with the published literature that NHEJ is the predominant contributor to DSB 









Figure 20. Relative percentage of NHEJ and MMEJ in cell in U2OS and A549 cells. Reprinted 
from (156) with permission from Oxford University Press. 
 
3.2.2 MMEJ is Enhanced When End Cleaning is Inhibited 
Because ligation requires removal of the 3’ P at DNA termini by PNKP (116), we tested 
the effect of PNKP deficiency on MMEJ. We analyzed end joining of pNS in A549 cells in 
which PNKP was depleted via stable expression of its shRNA (117). The frequency of MMEJ in 
PNKP-depleted cells was 3-fold higher compared to that in the wild type (WT) cells, which was 
reversed by ectopic expression of WT-PNKP but not by the phosphatase-inactive mutant (Figure 
21). These results strongly suggest that NHEJ involves 3’ P removal by PNKP, as reported 
earlier (115), and that its deficiency promotes MMEJ-mediated DSB repair. Although it has been 
suggested that PNKP promotes MMEJ in vitro via its interaction with PARP1-XRCC1/LIG3 













































Figure 21. End-cleaning by PNKP promotes NHEJ. (A) In cell repair of pNS in WT 
A549 cells, shRNA-mediated PNKP-depleted cells, or in endogenous PNKP-depleted cells with 
transient expression of HA-tagged PNKP-WT or PNKP-phosphatase/kinase inactive (PK-) 
mutant. (B) Western analysis of extracts from cells in (A). Reprinted from (156) with permission 
from Oxford University Press. 
 
3.2.3 MMEJ is Enhanced After Ionizing Radiation 
We then asked whether MMEJ and NHEJ are affected in cells by radiation-induced 
activation of the DNA damage response signaling. We irradiated A549 and U2OS cells with 
various doses of X-rays immediately before transfection with pNS, and then analyzed sequences 
of the repaired plasmids. The contribution of MMEJ relative to NHEJ was enhanced ∼5-fold 
after exposure to a 0.5 Gy or higher X-ray dose in both cell lines (Figure 22). These results are 
consistent with a previous report of induction of MMEJ in yeast and mammalian cells after 







Figure 22. IR stimulates MMEJ. (A) In cell repair of pNS in control A549 cells and in cells 
preirradiated with various doses of X-rays, as indicated. (B) In cell repair of pNS in control 
U2OS cells and cells treated with different doses of X-rays, as indicated. Reprinted from (156) 
with permission from Oxford University Press. 
 
3.2.4 MMEJ After Ionizing Radiation Requires XRCC1, PARP1, MRE11, and CtIP 
We confirmed that MMEJ was not mediated by a variant NHEJ process, based on the 
result that MMEJ accounted for up to 95% of DSBR in U2OS cells when the cells were 
pretreated with the DNA-PK inhibitor NU7441. Furthermore, induction of MMEJ in 
preirradiated cells was absent if any of the known MMEJ factors, namely, XRCC1, PARP1, 
MRE11 and CtIP, were either depleted by treatment with cognate siRNA or inhibited by specific 
inhibitors (Figure 23).  
3.2.5 XRCC1 is Recruited to DSBs for Repair After Ionizing Radiation 
Based on our observation that MMEJ is compromised in XRCC1-deficient U2OS cells, 
and also on published reports documenting the involvement of XRCC1 in MMEJ-mediated 







Figure 23. MMEJ after IR depends on XRCC1, CtIP, PARP1, and MRE11. In cell repair of pNS 
in control U2OS cells and cells treated with different doses of X-rays, XRCC1 siRNA (100 nM, 
72 h), CtIP siRNA (100 nM, 72 h), rucaparib (10 μM), mirin (100 μM), or NU7441 (10 μM), as 
indicated. Reprinted from (156) with permission from Oxford University Press. 
 
Proximity ligation assay (PLA) for XRCC1 and the DSB marker γH2AX confirmed that XRCC1 
was recruited at DSBs in irradiated cell nuclei (Figure 24). Moreover, the number of PLA foci 
increased significantly after inhibition of DNAPK with NU7441, suggesting that XRCC1’s 
involvement in DSB repair is more pronounced when NHEJ is inhibited (Figure 24). Significant 
reduction in the number of PLA foci showing XRCC4-γH2AX co-localization in NU7441-







Figure 24. XRCC1 is recruited to DSBs after IR. PLA for XRCC1-γH2AX and XRCC4-
γH2AX interaction in U2OS control cells, and in irradiated cells with or without 10 μM Nu7441. 
Quantification of the mean number of PLA foci per cell is shown in the right panel. Reprinted 
from (156) with permission from Oxford University Press. 
 
Because we and others have observed that PARP1 is required for MMEJ (120), and 
assists recruitment of XRCC1 to SSBs (121), we asked if PARP1 regulates XRCC1 recruitment 
to DSBs. However, the number of XRCC1-γH2AX PLA foci were not reduced in irradiated cells 
pretreated with PARP1 inhibitor compared to that in control cells (Figure 25). This strongly 
suggests that while PARP1 stimulates MMEJ, it is not a rate-limiting factor for XRCC1 
recruitment to DSBs, unlike SSB repair (122). Reduced auto-poly(ADP)-ribosylation of PARP1 
in Rucaparib-treated cells confirmed PARP1 inhibition (Figure 25).  
XRCC1’s role in DSB repair was further confirmed by the increase in γH2AX foci level 
and their delayed disappearance in U2OS cells after combined depletion of XRCC1 and DNA-
PK inhibition relative to DNA-PK inhibition alone (Figure 26). XRCC1-depleted cells also 
showed higher radiosensitivity than the control cells when treated with the DNAPK inhibitor 






NHEJ. This conclusion is further supported by earlier studies showing DSB accumulation in the 
Arabidopsis genome after loss of XRCC1 (123). 
 
Figure 25. XRCC1 recruitment to DSBs is independent of PARP1 activity. (A) PLA for 
XRCC1-γH2AX interaction in control U2OS cells, and in irradiated cells with or without 10 μM 
rucaparib. Quantification of the mean number of PLA foci per cell is shown in the lower panel. 
(B) Western analysis for poly-ADP-ribosylated (ADPR) PARP1 of cell extracts from U2OS 
control cells, and irradiated cells with or without 10 μM rucaparib. Reprinted from (156) with 
permission from Oxford University Press. 
 
3.2.6 CK2 Phosphorylation of XRCC1 Drives Formation of the XRCC1-MMEJ Complex 
CK2-catalyzed phosphorylation of XRCC1 promotes SSBR by enhancing its interaction 
with LIG3 and PNKP (84,124). We tested if enhanced MMEJ activity in irradiated cells is also 

























Figure 26. XRCC1 depletion affects DSBR and cell survival after IR. (A) γH2AX 
immunostaining in U2OS cells transfected with control siRNA or XRCC1 siRNA, with or 
without NU7441 treatment. Cells were fixed 1 h after irradiation with various doses of X-rays. 
(B) Kinetics of γH2AX foci disappearance in the same set of cells at different time points (15 
min, 1, 3, 6 h) following treatment with 3 Gy X-rays. (C) Clonogenic survival analysis for the 
same set of U2OS cells treated with X-rays (0, 1, 3, 6, 9 Gy). Plating efficiency (PE) for each set 










Figure 27. CK2 recruits XRCC1 to DSBs. (A) Western analysis of CK2αin XRCC1-FLAG IP 
with and without X-ray treatment. (B) XRCC1-CK2α PLA. (C) CK2α immunostaining in control 
and irradiated cells. (D) Western blot analysis of phosphorylated XRCC1 in U2OS control cells, 
irradiated cells, and cells treated with CX-4945 (25 μM, 50 μM) prior to irradiation. (E) PLA for 
phospho-XRCC1-γH2AX interaction in control cells, and irradiated cells with or without CX-
4945 (50 μM) treatment. Reprinted from (156) with permission from Oxford University Press. 
 
expressing ectopic XRCC1-FLAG showed a significant increase in CK2α level after irradiation 
with 3 Gy of X-rays, consistent with an increase in the number of nuclear PLA foci for XRCC1- 
CK2α (Figure 27). CK2 activated by stress signaling translocates to the nuclei after irradiation 
(125), where it colocalizes with γH2AX foci (126). We observed CK2α localization to the nuclei 
of irradiated U2OS cells, together with an increase in phosphorylation of XRCC1 at 






27). Furthermore, the phospho-XRCC1-γH2AX PLA foci in irradiated cells indicated 
localization of phosphorylated XRCC1 at DSBs, which was blocked by CX-4945 (Figure 27). 
The 3’ ssDNA overhang, a prerequisite for stabilizing DSB termini via microhomology-
dependent annealing in MMEJ, is generated by the end processing nucleases MRE11 and CtIP 
(103,127,128); however, their role in coordinating MMEJ is not clearly understood. Because we 
observed recruitment of XRCC1 at X-ray-induced DSBs, we tested the role of XRCC1 in 
assembling the MMEJ complex. We isolated IPs of endogenous XRCC1 or XRCC1-FLAG from 
nuclear extracts of control U2OS cells or those transiently expressing XRCC1-FLAG, and 
identified MRE11 and CtIP in the IPs (Figure 28). The levels of these proteins in the IPs 
increased after irradiation (Figure 28). The XRCC1 level in the U2OS nuclear extract also 
increased after irradiation; however, its interaction with MRE11 and CtIP was prevented in cells 
pretreated with CX-4945, which was further confirmed by PLA analysis (Figure 28).  
We then analyzed FLAG-IP from U2OS nuclear extracts transiently expressing, at a 
comparable level, XRCC1-WT or non-phosphorylable XRCC1-CKM-FLAG (each of the eight 
primary serine/threonine CK2 target sites within the linker domain mutated to alanine). We 
observed a significant increase in MRE11 and CtIP levels in the XRCC1-WT-FLAG-IP but not 
in XRCC1-CKM-FLAG-IP isolated from irradiated cells (Figure 29). This confirmed that CK2-








Figure 28. CK2 is required for MMEJ complex formation. (A) Western blot analysis of 
XRCC1, phospho-XRCC1, MRE11, CtIP, and LIG3 in endogenous XRCC1-IP isolated from 
nuclear extract of U2OS cells pretreated with X-rays (3 Gy) and/or CX-4945 (50 μM) treatment 
as indicated. (B) PLA for XRCC1-MRE11 (top panel) and XRCC1-CtIP (bottom panel) 
interactions in U2OS cells with the same treatments. Reprinted from (156) with permission from 


















Figure 29. CK2 phosphorylation of XRCC1 is required for MMEJ complex formation. (A) PLA 
for interaction of MRE11 and CtIP with XRCC1 WT-FLAG (left panels) or XRCC1 CKM-
FLAG (right panels) in control or irradiated cells. (B) Western blot analysis of MRE11 and CtIP 
in XRCC1 WT- or XRCC1 CKM-FLAG IP isolated from nuclear extract of U2OS cells 
transiently expressing XRCC1 WT- or XRCC1 CKM-FLAG. Reprinted from (156) with 
permission from Oxford University Press. 
 
3.2.7 XRCC1-MRE11 Interaction is Not Mediated by LIG3/NBS1 
The XRCC1/LIG3 complex has been shown to interact with the MRN complex via the 
BRCT domain of LIG3 and the FHA domain of NBS1 (30). However, we found that the level of 
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(Figure 30), strongly suggesting direct interaction between XRCC1 and MRE11 rather than 














Figure 30. XRCC1 and MRE11 do not interact through Ligase 3/NBS1. Western blot 
analysis of MRE11, LIG3 and NBS1 in XRCC1-FLAG IP from control or irradiated U2OS cells 
transfected with XRCC1-WT-FLAG (48 h), and scrambled (Sc), LIG3, or NBS1 siRNA (100 
nM, 72 h), as indicated. Reprinted from (156) with permission from Oxford University Press. 
 
3.2.8 CK2 Phosphorylation of XRCC1 Promotes MMEJ 
Based on the observation that irradiation enhances the XRCC1-MRE11/CtIP interaction 
via XRCC1 phosphorylation, we tested if CK2 inhibition or depletion reduces MMEJ activity. 
Significant reversal of radiation-induced MMEJ in U2OS cells pretreated with CX-4945 or 
CK2α siRNA suggests a critical role of CK2-mediated XRCC1 phosphorylation in MMEJ 
(Figure 31). This was further supported by restoration of radiation-induced enhancement of 
MMEJ by ectopic WT-XRCC1 but not the phosphomutant XRCC1-CKM in cells depleted of 
endogenous XRCC1, even though the ectopic proteins were similarly localized at the DSB sites 
(Figure 31).  




















Figure 31. CK2 phosphorylation of XRCC1 promotes MMEJ in cell. (A) In cell repair of pNS, 
in control or preirradiated U2OS cells, pretreated wih CX-4945 (25 μM). (B) Western analysis 
for endogenous XRCC1 and ectopic XRCC1 WT- or XRCC1 CKM-FLAG after XRCC1 3’ 
UTR siRNA treatment. (C) In cell repair of pNS in U2OS cells transfected with either empty 
vector, XRCC1 WT-FLAG or XRCC1 CKM-FLAG plasmids, along with either scrambled 
siRNA or XRCC1 3’ UTR siRNA, as indicated, with/without preirradiation. Reprinted from 
(156) with permission from Oxford University Press. 
 
3.2.9 XRCC1 Performs MMEJ In Vitro 
Because we detected XRCC1 interaction with the DSB processing nucleases MRE11 and 
CtIP, we asked if the XRCC1-IP could carry out MMEJ in vitro. The XRCC1-FLAG IP isolated 
from the nuclear extract of U2OS cells expressing ectopic XRCC1-FLAG was incubated with 
pNS for 30 minutes at 37°C in a buffer containing ATP and dNTPs, and supplemented with 
purified recombinant protein complex XRCC1/LIG3α, followed by incubation for 15 h at 16°C 




























Figure 32. Schematic outline of MMEJ in vitro assay using XRCC1-FLAG IP. Reprinted from 
(156) with permission from Oxford University Press. 
 
After transformation, the plasmids recovered from E. coli showed that XRCC1-FLAG IP 
was able to carry out MMEJ in vitro with moderate efficiency (Figure 33). However, unlike 
plasmids recovered after the in cell repair of pNS, which showed both NHEJ and MMEJ 
products, only MMEJ products were observed for the plasmid substrate repaired in vitro with 
XRCC1-IP. This was expected because the XRCC1-IP should contain only proteins involved in 
MMEJ/BER, and not in NHEJ. This novel observation provides the first direct evidence for a 
specific MMEJ protein complex functioning in cell. Irradiation of U2OS cells before isolation of 
the XRCC1 IP increased its MMEJ activity (Figure 33), consistent with the in cell data. 
Importantly, pretreatment of the XRCC1-FLAG IP with the MRE11 inhibitors mirin and PFM03 


















(129) strongly inhibited MMEJ activity (Figure 33), further validating the in vitro assay and 
supporting the functional requirement for both MRE11’s exonuclease and endonuclease 
activities in MMEJ. Moreover, pretreatment of cells with CX4945 prior to isolation of XRCC1 
IP reduced the ability of the isolated complex to carry out MMEJ in vitro (Figure 33). This 
supports our in cell results showing the requirement for CK2-mediated XRCC1 phosphorylation 
for MMEJ. We further confirmed this by comparing MMEJ activity in FLAG-IPs isolated from 
cells ectopically expressing XRCC1-WT- or XRCC1-CKM-FLAG (Figure 33). Although 
significantly lower than XRCC1-WT-IP, XRCC1-CKM-IP from irradiated cells showed some 
activity in plasmid circularization, presumably because it partially mimics phosphorylated 
XRCC1. 
3.2.10 XRCC1 Interacts Directly With MRE11 In Vitro 
Based on our findings that the LIG3/NBS1 interface does not mediate the XRCC1-MRE11 
interaction, we decided to test whether purified XRCC1 and MRE11 interacted in vitro. Full-
length XRCC1-His tagged and XRCC1-GST tagged, and three truncated forms, one lacking the 
NTD and first linker region (Δ293-XRCC1-GST), the second consisting of only the BRCT1 
domain (BRCT1-XRCC1-GST), and the third consisting of only the BRCT2 domain (BRCT2-
XRCC1-GST), were purified from E. coli. Full length MRE11-FLAG was a gift from Tanya 
Paull. MRE11 regions encompassing aa 1-273 (MRE11-A-GST), aa 223-535 (MRE11-B-GST), 
and aa 487-708 (MRE11-C-GST) were purified from E. coli.  Purified proteins were incubated 
for 1h at 4°C, followed by addition of either Ni-NTA beads (for His-tag isolation) or FLAG 
beads (for FLAG isolation). After washing, proteins were eluted with 2X LDS and run on a 
NuPage gel. We found that the Δ293-XRCC1-GST construct was able to pull down full-length 





















Figure 33. CK2 phosphorylation of XRCC1 promotes MMEJ in vitro. (A) Mean number of 
colonies obtained from the in vitro repair assay with empty vector (EV) or XRCC1-FLAG IP 
from control, irradiated cells and those treated with CX-4945 before irradiation; XRCC1-FLAG 
IP from irradiated cells was separately incubated with 100 μM mirin or PFM03 before 
performing in vitro repair of pNS. The amount of IP used was normalized to the XRCC1 level. 
(C) In vitro repair of pNS with XRCC1 WT or XRCC1 CKM-FLAG IP from control or 
irradiated cells. Western blot analysis of XRCC1-FLAG levels in the IPs for each experiment are 









Figure 34. XRCC1 and MRE11 interact in vitro. (A) In vitro pulldown of XRCC1-His incubated 
with various MRE11-GST domains with Ni-NTA beads. (B) In vitro pulldown of MRE11-FLAG 
incubated with various XRCC1-GST domains with FLAG beads. Reprinted from (156) with 









indicating that this interaction was specific to the BRCT1 domain (Figure 34). Pulldown of full-
length XRCC1 with domains of MRE11 indicated that XRCC1 interacts specifically with the C-
terminal region of MRE11 (Figure 34). 
3.3 Discussion 
         NHEJ, the predominant pathway for DSB repair in the human genome in both growing and 
quiescent cells, repairs ∼75% of DSBs within 30 min (8). However, DNA breaks with complex 
damage, such as those induced by IR, require additional processing and may therefore not be 
repaired via NHEJ (130). For such complex breaks, slower repair processes that involve end 
trimming, such as accurate HR or error-prone MMEJ, may be critical. While HR critically 
contributes to DSB repair in the replicating cancer cell genome, MMEJ’s role in survival of 
cancer cells is becoming increasingly evident, particularly in cancers with HR defects (24). 
Furthermore, MMEJ could be particularly pronounced in DSB repair at repetitive sequences, 
which are abundant in mammalian genomes(131). Thus, the microhomology sequences observed 
at chromosomal breaks in many cancers implicate MMEJ in DSBR and radioresistance 
(108,132). In order to unravel the regulation, molecular mechanisms and prevalence of MMEJ, it 
is important to establish cellular and in vitro assays for this pathway of DSB repair. To explore 
repair of IR-induced DSBs containing 3’-blocked termini (132), we developed a linear plasmid 
substrate containing 3’P and DSB-flanking microhomology sequences, and were able to estimate 
the relative contribution of NHEJ and MMEJ to DSB repair. Although the particular sequence 
arrangement in this plasmid may not commonly occur in the human genome, it does represent 
genomic DSBs with microhomology sequences, and thus facilitates identification of the 
parameters that regulate MMEJ. In spite of the presence of microhomologies, NHEJ was found 






is in agreement with published reports of the comparatively a minor contribution of MMEJ to 
DSB repair in normal human cells. At the same time, this provides strong validation for our 
assay. While our system of repairing naked plasmid DNA does not completely simulate DSB 
repair at the chromatin level, and cannot exclude possible nonspecific degradation of the DNA 
substrate during its intracellular transit, it recapitulates the known requirements for NHEJ and 
MMEJ in mammalian genomes. Thus, this straightforward assay allowed us to identify external 
factors, such as radiation exposure and kinase signaling, that regulate MMEJ. Moreover, our 
discovery of the ability of XRCC1-IP to carry out MMEJ in vitro (in which no possibility of 
intracellular nonspecific substrate degradation exists) provides an opportunity for establishing 
biochemical requirements for MMEJ.  
          During elucidation of BER mechanisms, the formation of dynamic repair complexes that 
enhance repair of diverse DNA lesions in response to genotoxic stress has been documented 
(133-135). It is evident that the formation of such complexes is facilitated by the nonenzymatic 
scaffold protein XRCC1. The stability of such repair complexes is likely to be dependent on 
binary interactions among the components of the complex, which are modulated by their 
reversible, covalent modifications (136). In delineating the mechanisms of MMEJ, we 
discovered XRCC1’s key role in this repair pathway. Because XRCC1 appears to be limiting in 
MMEJ, we tested whether radiation-induced covalent modifications of XRCC1 promote its 
interactions and involvement in MMEJ. XRCC1 is phosphorylated at multiple sites, particularly 
at the linker regions between the conserved domains (137). Notably, CK2-mediated 
phosphorylation of XRCC1 at the inter-BRCT domain linker region prevents proteasomal 
degradation (83), and also reduces its affinity for naked DNA (84). Thus, XRCC1, normally 






repair complexes, mediated by interactions involving its conserved N-terminal and BRCT 
domains, as well as the unstructured linker domains. Here, we have shown that XRCC1 depends 
on CK2-mediated phosphorylation for its interaction with MRE11 in irradiated cells, distinct 
from the interaction between the XRCC1-LIG3 and MRN complexes occurring via LIG3-BRCT 
and NBS1-FHA domains (30). Our identification that XRCC1 and MRE11 interact in vitro 
supports the model where MRE11 and XRCC1 interact directly to mediate repair. Our data 
suggest that phospho-XRCC1 directly interacts with MRE11, which could be further stabilized 
by LIG3-NBS1 interaction. Hence, it is possible that XRCC1 is recruited at DSBs via MRN 
rather than PARP1, as is currently believed (104). Future structural studies may illuminate how 
XRCC1’s conformational changes induced by phosphorylation facilitate specific protein-protein 
interactions. Importantly, we have shown that the induction of XRCC1 repair complexes via IR-
induced CK2 phosphorylation could account for the increase in MMEJ-mediated DSBR in 
irradiated cells. Based on such a scenario, it would be worth investigating how MMEJ is affected 
by XRCC1 phosphorylation at other sites by CHK2 and DNA-PK (137). MMEJ, which utilizes 
the SSBR proteins, is distinct from the HDR and NHEJ pathways for DSB repair. However, 
several variations of MMEJ likely exist depending on the cell type and the nature of DNA strand 
breaks. For example, XRCC1 is apparently dispensable for Alt-EJ/MMEJ mediated class-switch 
recombination or IgH/c-myc translocation in XRCC4-deficient B cells (139). This is evidently 
distinct from the MMEJ of IR-induced DSBs. The clustered damage induced by IR in the 
genome contains a large number of closely spaced bi-stranded lesions that could lead to 
secondary DSBs formed as BER intermediates (52). These secondary DSBs, possibly with 
ssDNA overhangs, have poor affinity for Ku, whose binding to the DSB termini is a prerequisite 






whose initiation is dependent on the recruitment of the SSB factors XRCC1 and PARP1, which 
compete with Ku (20). Additionally, in the absence of microhomology spanning the DSB, 
MMEJ could utilize microhomology sequences synthesized de novo, for which Pol θ is a likely 
candidate. Another unanswered question that our assay helps address is how resection at the 
DSB termini regulates MMEJ. Both MMEJ and HR require generation of 3’ overhangs through 
resection at the 5’ end. Nonetheless, a profound difference exists between the extended overhang 
required in HR versus the short overhang promoting MMEJ. We have shown that MMEJ is 
dependent on both endo- and 3’ →5’ exonuclease activities of MRE11, as was also shown in HR 
(129). Furthermore, the endonuclease inhibitor showed a stronger inhibitory effect on MMEJ, 
suggesting that an initial endonuclease nick followed by exonuclease excision generates the 3’ 
overhang at blocked DNA breaks in irradiated cells. Overall, the contribution of MRE11, CtIP, 
EXO1 and DNA2 to excision during DSBR is poorly understood (142). Our results have 
established a functional role for both nuclease activities of MRE11 in MMEJ. However, 
extensive end resection by MRE11/CtIP could lead to generation of long ssDNA overhangs 
where RPA binding would inhibit MMEJ (143). It is therefore important to investigate if XRCC1 
regulates end resection at DSBs during MMEJ, similar to the BRCA2 and FANC protein-
mediated regulation of MRE11 activity for replication fork protection or inter-strand crosslink 
repair (47). In summary, we have shown that the contribution of MMEJ to DSB repair in the 
genome is affected by radiation exposure via enhancement of the formation of MMEJ-proficient 
XRCC1 complex. Paradoxically, radiation therapy, while killing tumor cells, may induce 
radioresistance in surviving cells by activating MMEJ to repair radiation-induced genome 
damage, possibly leading to increased mutations. It is possible that the altered phenotype caused 






tumor regrowth. Our results showing that XRCC1-MRE11 interaction, dependent on XRCC1 
phosphorylation by CK2, activates MMEJ, suggests that this interaction could be a potential 
therapeutic target for inhibiting MMEJ, thereby increasing radiosensitivity of cancer cells. 
 
Figure 35. Model for activation of XRCC1-MMEJ repair complex by CK2 after IR. In cancer 
cells treated with X-rays, CK2 is activated, localizes to the nucleus, phosphorylates XRCC1 
bound to chromatin or in the nuclear lamina, and promotes the formation of MMEJ complexes 
that consist of MRN, CtIP, LIG3 and possibly other MMEJ factors such as DNA polymerases. 
The active XRCC1 repair complexes then localize to DSB sites (overt or secondarily generated) 
to carry out MMEJ, possibly competing with or complementing NHEJ. MRE11 endonuclease 














4. XRCC1 PROMOTES MUTAGENIC DNA REPAIR AND REGULATES 
REPLICATION FORK DYNAMICS IN BRCA2-DEFICIENT CELLS* 
4.1 Introduction 
Mutations can confer selective growth advantages on cancer cells, which leads to their 
clonal selection and expansion. DNA damage due to high levels of oxidative stress and 
replication stress, in combination with aberrant DNA repair mechanisms, drives mutation 
accumulation and genomic instability in cancer cells. Chemoradiation therapy induces DNA 
damage in order to kill cancer cells, however, DNA repair processes can lead to post-therapy 
survival of cancer cells (92). 
DNA double-strand breaks (DSBs) are the most lethal DNA damage, which are induced 
by cancer therapies, replication stress, and oxidative stress (52). DSBs generated during S/G2 
phases of the cell cycle are typically repaired accurately via homologous recombination (HR), 
which utilizes the undamaged sister chromatid as a template (17). Several HR factors, including 
BRCA1, BRCA2, PALB2, and RAD51, have been identified as cancer susceptibility genes 
(144). When they are mutated or deleted, HR is impaired, and DSBs that arise during S/G2 
phases have to rely on alternative pathways for repair, which are often error-prone (24-26,64,65). 
These breast cancer susceptibility genes have also been found to have HR-independent roles in 
replication fork protection (44,46). In their absence, stalled forks are degraded by nucleases, 
including MRE11. This degradation also depends on a number of other factors, including 
 
*Parts of this chapter are reprinted with permission from “XRCC1 promotes replication restart, 
nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells” by Eckelmann 
B, Bacolla A, Wang H, Ye Z, Guerrero EN, Jiang W, et al., 2020. Nucleic Acids Research 






PARP1, and replication restart of degraded forks has been demonstrated to contribute to genome 
instability of HR-deficient (HRD) tumors (145-147). 
Genome instability arising from error-prone DSB repair and restart of degraded forks has 
been observed in whole-genome sequencing studies of HRD tumors. A specific mutational 
signature, signature 3, characterized by chromosomal translocations whose breakpoints are 
flanked by microhomology (MH) sequences, is associated with HRD tumors (60,144,148-151). 
Whether these rearrangements result from HR failure at DSBs, extensive fork degradation and 
restart, or both is unknown. Regardless, the observation of MH at breakpoints implicates 
microhomology-mediated end joining (MMEJ), a backup, error-prone repair pathway, in DSB 
repair and/or fork restart in these tumors. 
MMEJ involves limited resection at DSBs by the MRE11 and CtIP nucleases, gap filling 
synthesis by DNA polymerase θ (POLQ), scaffolding by XRCC1, and ligation by DNA ligase 1 
or 3 (LIG1/LIG3) (19). MMEJ was discovered as a backup end-joining pathway for non-
homologous end-joining (NHEJ), which directly joins two double-stranded DNA ends, and has a 
minor role in NHEJ and HR-proficient cells. Despite its minor role, MMEJ contributes to 
chromosomal rearrangements and genomic instability in aneuploid cancer cells (108,152), which 
tolerate MMEJ-mediated mutations. Recent studies showed that MMEJ is also a backup pathway 
for HR, as it is upregulated in BRCA2-deficient tumors, where POLQ in particular is critical for 
genome maintenance and tumor survival (24-26,64,65). Several MMEJ factors, including POLQ, 
PARP1, and XRCC1 were identified as synthetic lethal with BRCA2 in a recent CRISPR screen 
(67). Previous reports have implicated XRCC1 in genomic stability of HRD breast and ovarian 






XRCC1 canonically coordinates base excision repair (BER) and single-strand break 
repair (SSBR), through scaffolding and stimulation of several factors involved in these repair 
pathways (81). Recent evidence point towards additional roles of XRCC1 in DNA metabolism 
beyond these functions, specifically in DSB repair (DSBR) and the resolution of DNA 
replication intermediates (3,30,75,89,90). We recently observed that XRCC1 plays a direct role 
in MMEJ, an alternative form of DSBR, by scaffolding MRE11 and CtIP in response to radiation 
to form a MMEJ-competent complex (156). Collectively, these observations led us to 
hypothesize that XRCC1 has a role in resolving single-ended DSBs (seDSBs) that arise at 
collapsed replication forks through a MH-based mechanism. 
Whether XRCC1 and MMEJ have roles in resolving stalled and collapsed replication 
forks in HRD tumors is a critical question. The efficacy of PARP inhibitors (PARPi) in HRD 
tumors may be linked to the role of XRCC1 in these tumors, as XRCC1 is one of the primary 
targets of PARP1 (157). Additionally, POLQ is a promising chemotherapeutic target in HRD 
tumors, and discovering how it participates in active repair complexes is an important goal. 
In this study, we have examined the role of XRCC1 in HRD cancers using several approaches. 
We show that replication fork collapse stimulates a MH-based repair process that involves 
formation of a MMEJ-competent XRCC1 complex containing end resection factors and DNA 
polymerases. This process is suppressed by BRCA2, implicating XRCC1 in MMEJ in HRD 
cancers. We find that XRCC1 promotes replication fork restart, and discover that XRCC1 
promotes stalled fork degradation in BRCA2-deficient cells. Our findings thus provide 
mechanistic insight into the MMEJ pathway in HRD cells, and add evidence to the growing 
connection between MH usage in DSBR and replication fork protection and restart, with broad 






expression program in HRD cells that may be linked to platinum and PARPi sensitivity of these 
tumors. 
4.2 Results 
4.2.1 XRCC1 has a Minor Contribution to Cellular Survival and DSB Repair After 
Replication Stress in HR-proficient Cells 
DSBs arising during S/G2 phases of the cell cycle are typically repaired via HR (17). 
High levels of replication stress that occur in cancers lead to increased levels of S/G2 DSBs 
(158), and when HR is defective in cancer cells, alternative methods of DNA repair have to be 
engaged during S/G2 phases for cell survival (26). However, seDSBs that result from replication 
stress and replication fork collapse are not preferred substrates for NHEJ (45). Whether these 
seDSBs are a substrate for MMEJ or related repair pathways is an important question in cancer 
biology. Previous studies (26,43,103,159) have suggested that replication stress causes DSBs 
that can be repaired via MMEJ. Whether XRCC1 is involved in MMEJ after replication stress, 
and in particular in BRCA-deficient cancer cells, is unknown. 
Based on our identification of XRCC1 as a critical component of MMEJ (156), in 
addition to observations that XRCC1-depleted cells are sensitive to ATR inhibition (160), we 
explored XRCC1’s role in the replication stress response. Hydroxyurea (HU), an inhibitor of 
ribonucleotide reductase (RNR), depletes the cells of deoxyribonucleotides, causing replication 
fork stalling (161). ATR prevents fork collapse in several ways, and the combination of HU with 
an ATR inhibitor (ATRi) is known to cause fork collapse (162). Downregulation of XRCC1 by 
siRNA was confirmed by Western Blotting (Figure 36). Survival assays indicate that XRCC1-
depleted cells are mildly sensitive to HU and VE-821, an ATRi (Figure 36). The neutral comet 








































Figure 36. XRCC1 is moderately involved in DSBR in HR-proficient cells. (A) Western Blot of 
XRCC1 depletion by siRNA. (B) Clonogenic survival assay of XRCC1-depleted cells to ATRi. 
(C) Clonogenic survival assay of XRCC1-depleted cells to HU. (D) Relative fraction of U2OS 
cells positive for the DSB marker γH2AX by immunofluorescence. Cells were treated with 3mM 
HU for 3h and then allowed to recover for the indicated times. Cells were marked positive if they 
contained more than 10 foci. (E) Neutral comet assay in ctrl and XRCC1 siRNA-treated cells 





















36). We monitored the DSB marker γH2AX after treatment with HU and found that XRCC1-
depleted cells had moderately more persistent DSBs than control cells (Figure 36). These results 
collectively indicate that XRCC1 does not significantly promoting DSBR after replication stress 
in WT cells, in contrast to its clear role in HR-deficient cells that we describe later, consistent 
with the established minor role for MMEJ in HR-proficient cells. 
4.2.2 XRCC1 is Recruited to Sites of Replication Stress to Complex with Diverse DNA 
Repair Factors 
We identified distinct XRCC1 foci that formed in response to both HU and HU+ATRi (Figure 
37), which colocalized with yH2AX (Figure 37). To determine whether XRCC1 is recruited to 
stalled and collapsed replication forks, we utilized the proximity ligation assay (PLA), which 
produces a fluorescent focus when two distinct antibodies are in close proximity (~40 nm; 
Duolink). Briefly, we pulse labeled asynchronous U2OS cells with BrdU, then treated them with 
HU or ATRi+HU for the indicated times. PLA analysis using BrdU and XRCC1 antibodies 









Figure 37. XRCC1 localizes to sites of replication stress. (A) XRCC1 foci formation after 
treatment of U2OS cells with 3mM HU and/or 3μM ATRi for 8h where indicated. (B) 
Colocalization of XRCC1 with γH2AX after ATRi+HU. (C) XRCC1 localization to sites of 
replication stress, as measured by BrdU-XRCC1 PLA Asynchronous cells were pulsed with 
10μM BrdU for 15 minutes before treatment with 3mM HU and/or 3μM ATRi for the indicated 
times. 
 
observed progressive recruitment of XRCC1 to sites of replication stress (Figure 37), consistent 






We then utilized PLA to quantify changes in interaction between XRCC1 and its partners 
in various DNA repair pathways. Marked increases in foci number were observed between 
XRCC1 and several DSBR and SSBR factors (Figure 38). The most prominent increases 
occurred between XRCC1 and MRE11, POLQ, and γH2AX, implying a role for XRCC1 in 
DSBR at sites of replication stress (Figure 38). The interaction between XRCC1 and POL, the 
canonical gap-filling polymerase in SSBR, decreased after replication stress, suggesting that 





Figure 38. XRCC1-PLA after replication stress. PLA between XRCC1 and the indicated factors 
in control cells and after treatment for 8h with 3mM HU and 3μM ATRi. 
 
4.2.3 Replication Stress Stimulates MMEJ via XRCC1 Repair Complex Formation 
Based on these observations that XRCC1 complexes with DSBR factors after replication 

























Figure 39. Replication stress stimulates EJ2-MMEJ. (A) Scheme for repair of I-SceI-
induced DSBs via MMEJ in the EJ2 U2OS cell line. (B) Repair of ISceI-induced DSBs after 
replication stress. EJ2 U2OS cells were treated with the indicated doses of HU and VE-821 





































Figure 40. Replication stress stimulates pNS-MMEJ. (A) Scheme for repair of pNS plasmid in 
mammalian cells after transfection. (B) Repair of linearized plasmid substrate pNS after 
replication stress. 
 
We utilized two separate MMEJ assay systems, the chromosomally integrated MMEJ reporter 
system (EJ2) developed by J. Stark (Figure 39) (112), which measures MMEJ by restoration of 
GFP after cutting by ISceI, and a linearized plasmid substrate system we previously established 
(Figure 40) (156), where MMEJ and NHEJ are scored separately based on the sequencing of 
DSB joints in recovered plasmids that are repaired in cell. Treating U2OS-EJ2 cells with HU or a 
combination of HU and ATRi led to an increase in the total number of MMEJ events (Figure 39). 
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Pre-treating U2OS cells with HU or HU+ATRi led to an increase in MMEJ events relative to the 
total number of end-joining events sequenced (Figure 40). These results indicate that replication 
fork collapse stimulates the MMEJ pathway, in agreement with previous observations (103). As 
expected, this stimulation was dependent on XRCC1, CtIP, and POLQ level, in addition to 
PARP1 and MRE11 activity (Figure 39). 
We have previously shown that MMEJ factors, including XRCC1, form a complex which 
when isolated via immunoprecipitation is able to carry out MH-based end joining of the 
linearized pNS plasmid (156). To quantify the ability of the replication stress-induced XRCC1 
complex to perform MMEJ and SSBR, we utilized two separate in vitro DNA repair assays. 
Briefly, we expressed FLAG-tagged XRCC1 in WT U2OS cells, then immunoprecipitated 
XRCC1-FLAG from control cells and cells treated with ATRi+HU. After washing, we incubated 
XRCC1-FLAG beads with linearized pNS substrate in reaction buffer. After ligation of the 
reaction mix, we transformed competent E coli cells with the reaction mix, and the number of 
colonies (reflecting individual repair events that restored expression of antibiotic resistance)  
were counted (Figure 41). We found that after ATRi+HU, the activity of the XRCC1 complex 
dramatically increased, indicating that XRCC1 is recruited to sites of replication stress to 
perform DSBR (Figure 41), as expected from the PLA data. All colonies sequenced were 
repaired via MMEJ (as expected with an XRCC1-IP). For assaying ligation activity, in vitro 
DNA nick ligation activity assays were performed with annealed nicked duplex oligomers 
labeled with Cy3 fluorescent dye (Figure 41). The direct ligation activity of the XRCC1 complex 
did not increase after ATRi+HU, suggesting that XRCC1 recruitment to collapsed replication 














































Figure 41. Replication stress stimulate MMEJ in vitro. (A) In vitro MMEJ repair activity assay 
scheme. (B) MMEJ repair activity of XRCC1 FLAG-IP with and without ATRi+HU treatment. 
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4.2.4 BRCA2 and XRCC1-depleted Cells are Sensitive to Replication Stress and Repair 
DSBs Inefficiently 
BRCA1/2 deficiency is strongly associated with mutational signatures characterized by 
microhomology at chromosome breakpoint junctions (60). This, in addition to other evidence 
(24-26), suggests that HRD tumors utilize MMEJ for DSBR, which promotes chromosomal 
rearrangements and genomic instability. Whether increased MMEJ usage in HRD tumors is the 
reason for the synthetic lethal relationship between BRCA2 and XRCC1 (67,153) is unknown. 
 
Figure 42. Effect of BRCA1/2 depletion on EJ2-MMEJ. 
 
We decided to explore the relationship between XRCC1 and BRCA2 to understand the 
mechanistic basis for this synthetic lethality. First, we used BRCA1 and BRCA2-specific 
siRNAs to assess their role in replication stress-induced MMEJ. BRCA2 depletion led to a 






MMEJ events (Figure 42), in agreement with previous work (65,163) although there is 
























Figure 43. XRCC1 depletion in BRCA2-deficient cells affects sensitivity to replication stress. 
(A) Western Blot of inducible knockdown of BRCA2 in scr-U2OS and B2-U2OS cells. (B) 
Clonogenic survival of scr-U2OS and B2-U2OS XRCC1-depleted cells to ATRi+HU. 
 
 
To examine the relationship between XRCC1 and BRCA2, we utilized a set of isogenic 
U2OS cells with integrated TRIPZ inducible shRNA for BRCA2, as well as a scrambled control. 
This tet-on system allows for reversible knockdown of BRCA2 in the presence of doxycycline 
(Figure 43). BRCA2-deficient cells were depleted of XRCC1 using siRNA, and then subjected to 
replication stress treatment with ATRi+HU. BRCA2-XRCC1 co-depleted cells were more 
sensitive to ATRi+HU (Figure 43), accumulated more DSBs (Figure 44), and repaired DSBs less  
















































Figure 44. XRCC1 affects DSBR in BRCA2-deficient cells. (A) Neutral comet assay in scr-
U2OS and B2-U2OS cells treated with ctrl and XRCC1 siRNA and/or HU. (B) Relative fraction 
of scr-U2OS and B2-U2OS cells positive for the DSB marker γH2AX by immunofluorescence. 
XRCC1 or ctrl siRNA-treated cells were treated with 3mM HU for 3h and then allowed to 











efficiently (Figure 44), indicating that XRCC1 has a higher level of engagement in DSBR in 
BRCA2-deficient cells relative to WT cells.  
4.2.5 BRCA2 Suppresses MMEJ by Preventing XRCC1 Recruitment and Repair Complex 
Formation 
We examined XRCC1 localization and complex formation in BRCA2-deficient cells. 
More XRCC1 foci formed in response to replication stress in BRCA2-deficient cells than control 











Figure 45. XRCC1 recruitment to sites of replication stress is suppressed by BRCA2. (A) 
XRCC1 foci formation after treatment of scr-U2OS or B2-U2OS cells with 3mM HU and/or 
3μM ATRi for 8h where indicated. (B) XRCC1 localization to sites of replication stress in scr-
U2OS or B2-U2OS cells, as measured by BrdU-XRCC1 PLA. Asynchronous cells were pulsed 
with 10μM BrdU for 15 minutes before treatment with 3mM HU and/or 3μM ATRi for the 
indicated times. 
 
Using PLA between XRCC1 and BrdU as described previously, we found that knockdown of 







Knockdown of BRCA2 also led to a marked increase in XRCC1 interaction with yH2AX, 
PARP1, and MRE11, as measured by PLA (Figure 46). These data strongly suggest that BRCA2 
suppresses MMEJ through suppression of the XRCC1-MMEJ complex. 
We expressed human POLQ-FLAG in both BRCA2-proficient and BRCA2-deficient 
U2OS cell lines. After inducing replication stress, we immunoprecipitated POLQ-FLAG and 
used Western Blot to detect XRCC1 and MRE11 in complex with POLQ. BRCA2 significantly 
suppressed interactions between POLQ and both XRCC1 and MRE11 (Figure 46). We then 
utilized in vitro repair assays as before to quantify the relative repair activities of XRCC1-FLAG 
IP from BRCA2-depleted and control cells. We found that XRCC1-FLAG IP from BRCA2-
depleted cells performed MMEJ at a much higher level than control cells (Figure 47). XRCC1-
FLAG IP performed SSBR at a moderately higher level in BRCA2-depleted cells relative to 
control cells (Figure 47). Together these data indicate that BRCA2 suppresses formation of the 
































Figure 46. BRCA2 suppresses XRCC1-MMEJ complex formation. (A) PLA between 
XRCC1 and the indicated factors in scr-U2OS and B2-U2OS cells treated for 8h with 3mM HU 
and 3μM ATRi. (B) Western Blot of POLQ-FLAG IP from scr-U2OS and B2-U2OS cells with 
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Figure 47. BRCA2 suppresses XRCC1-MMEJ repair activity. (A) MMEJ repair activity of 
XRCC1 FLAG-IP from scr and B2 cells treated with ATRi+HU. (B) Nick ligation assay scheme. 
Nick ligation activity of XRCC1-FLAG IP from scr and B2 cells treated with ATRi+HU. 
 
4.2.6 XRCC1 Contributes to Replication Fork Restart 
 
Based on our observations that XRCC1 is recruited to sites of replication stress to 
perform DSBR via MMEJ, we examined the effect of XRCC1 depletion on replication 
progression, replication fork protection, and replication restart using DNA fiber analysis (168). 
Some evidence for involvement of XRCC1 in replication restart exists (90), although its exact 
role is unclear. We found that XRCC1 depletion did not affect DNA replication progression 
(Figure 48) or fork protection (Figure 49) in WT U2OS cells. As expected, it did significantly 







X1-FLAG           -             +            + 
scr          scr         B2 
Unligated 
(24 nt) 























Figure 48. Effect of XRCC1 depletion on replication fork progression in U2OS cells.  Schematic 
of fork progression assay and representative images are shown. 
 
4.2.7 BRCA2 Changes the Effect of XRCC1 Depletion on Replication Fork Dynamics 
 
       A major phenotype of BRCA2-deficient cells is the degradation of nascent DNA at stalled 
forks by nucleases, including MRE11. Degradation of stalled forks leads to chromosomal 
aberrations and genomic instability (46). Based on our observations that XRCC1 scaffolds 
MRE11, and on published evidence for a pathway of break-induced replication (BIR) that 
depends on microhomology (MMBIR) (44,169-172) we depleted XRCC1 in our BRCA2-
depleted and control U2OS cell lines and examined replication fork dynamics. We found that 




































Figure 49. Effect of XRCC1 depletion on replication fork protection in U2OS cells.  Schematic 
of fork protection assay and representative images are shown. 
 
similarly to the effect of inhibition of the MRE11 nuclease by Mirin (Figure 52). This result 
suggests that XRCC1 cooperates with MRE11 in resection of stalled forks in BRCA2-deficient 
cells. We also found that the effect of XRCC1 depletion on fork restart is increased when 
BRCA2 is depleted (Figure 51). Collectively, these results reveal that XRCC1 plays specific 
roles in BRCA2-deficient cells in balancing the extent of fork degradation and fork restart to 
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Figure 50. Effect of XRCC1 depletion on replication fork restart in U2OS cells.  Schematic of 










































Figure 51. Effect of XRCC1 depletion on fork restart in scr-U2OS and B2-U2OS cells.  










































Figure 52. Effect of XRCC1 depletion and MRE11 inhibition on fork protection in scr-U2OS 

















4.2.8 DNA Repair Gene Expression is Correlated with Survival and HRD Mutational 
Signatures in Breast Cancer 
 
We examined the effect of XRCC1 expression on survival in breast cancer using 
available data from The Cancer Genome Atlas (TCGA) (173). We found that low expression of 
XRCC1 was associated with poor survival (Figure 53). Interestingly, close gene expression  
 
Figure 53. XRCC1 gene expression affects breast cancer survival. Survival curves of the 
top 50% (xrcc1_High) and bottom 50% (xrcc1_Low) XRCC1 gene expression groups of breast 







correlates of XRCC1 in breast cancer were all positive, and all were located in the same genomic 
region (19q13.3), and the DNA repair genes ERCC1 and PNKP were among the top 5 correlates 
(Table 5, Figure 54). The DNA repair genes ERCC2, POLD1, and LIG1 were also among the top 
correlates.  
Gene Name XRCC1 correlation p-value Genome Location  
ERCC1 0.621122 1.02057e-117 19q13.32 
PNKP 0.616526 1.57795e-115 19q13.33 
LIG1 0.487981 1.59022e-66 19q13.33 
ERCC2 0.462252 5.1842e-59 19q13.32 
POLD1 0.439 9.41139e-53 19q13.33 
Table 5. Gene expression correlates of XRCC1 on 19q13 involved in DNA repair. 
 
Figure 54. Organization of DNA repair genes in human 19q13.3. 
 
PNKP and ERCC1 expression were also associated with breast cancer survival (Figure 
55). We then examined whether XRCC1 expression was correlated with mutational signatures in 
breast cancer, as defined by Alexandrov et al. (59). There are roughly 30 mutational signatures in 
















Figure 55. PNKP and ERCC1 gene expression affect breast cancer survival. Survival 
curves of the top 50% (_High) and bottom 50% (_Low) PNKP and ERCC1 gene expression 
groups of breast cancer patients in TCGA. 
 
and XRCC1_high expression groups (Figure 56) we analyzed the enrichment of each of the 30 
mutational signatures in these groups. Of the 13 signatures occurring frequently in breast 
cancers, XRCC1 expression was associated with only signature 3 (Figure 56). Signature 3 is 
primarily associated with HRD and an elevated number of large insertions and deletions with 
overlapping microhomology at breakpoint junctions, characteristic of MMEJ (59). Surprisingly, 
the association of XRCC1 expression with Signature 3 enrichment was negative, contrary to our 
expectation that XRCC1 might be upregulated in BRCA-deficient, Signature 3 cancers to 
perform MMEJ. ERCC1 and PNKP expression were similarly negatively associated with 
Signature 3 (Figure 55). Remarkably, XRCC1, ERCC1, PNKP, and ERCC2 have all been 







therapies for HRD cancers. Thus, these results link the PARPi and platinum sensitivity of HRD 
tumors to a clustered gene expression program in these tumors. 
 
 
Figure 56. chr19q13.3 gene expression correlates with mutational signature 3 in breast cancer. 
(A) Signature 3 association with XRCC1_low, ERCC1_low, and PNKP_low expression groups. 
Mean Signature 3 score, standard deviation, and t-test P-value. The percentage of tumors within 
that group that have a nonzero Signature 3 score (%Sign_3) is also given along with Fisher’s 
exact test. (B) Gene expression of _low (blue) and high (gold) groups. Roughly the top 20% and 




4.3.1 MMEJ is Activated by Replication Stress 
 
The origin of microhomology at chromosome breakpoint junctions is an important topic 
in human genetics and disease. Generally, cellular stress, including replication stress, ionizing 
radiation, and metabolic stress, increases the usage of error-prone repair pathways to promote 
cell survival at the cost of genome stability (156,172,179). Increased genomic instability using 
MH-based pathways leads to copy number variation (CNV) (59), which contributes to genetic 
disorders and cancers (169,172), chromosome fragile site (CFS) breakage and repair, which can 







observed in several different cancers, including HR-deficient breast and ovarian cancers (59). 
Additionally, increased usage of MH-based pathways of repair may promote survival of cancer 
cells undergoing chemoradiation therapy (156,180,181).  
Chromosome rearrangements can be caused by replication-associated DSBs, which can 
be generated during replication by several different pathways (34). Critically, these DSBs are 
single-ended, precluding their repair by direct end-joining mechanisms and necessitating 
recombination. These structures can be repaired by the process of break-induced replication 
(BIR), which involves canonical HR factors including RAD51 (182). There is a RAD51-
independent method of BIR termed microhomology-mediated BIR (MMBIR), which utilizes 
MH to facilitate multiple template switching events (39,183). In situations where RAD51 is 
limiting, as in HDR cancers or hypoxia, replication-associated seDSBs cannot be repaired via 
BIR and instead use MMBIR (183,184). BIR/MMBIR models suggest that fork stalling and 
template switching to restart replication may be the cause of chromosomal breakpoint junctions. 
In this model, MH at chromosomal breakpoints in cancers reflects priming of replication using 
MH, indicating use of MMBIR for replication restart in these cancers (179). The enrichment of 
these breakpoints and the biological importance of MMEJ factors in HDR cancers suggest a 
connection between replication restart, fork protection, and MMBIR/MMEJ that warrants further 
exploration.  
Our finding that replication stress activates MMEJ and specific participation of MMEJ 
factors in the replication stress response is supported by previous observations (103,159), 
including the repair of replication stress-induced DSBs at CFS sites using MH (43). While the 
limitations of the systems used in this study prevent us from making any direct conclusions about 






resection and annealing, are still required in our systems. Thus, our observation that XRCC1 
forms a complex after replication stress that promotes resection and annealing of MH, and 
facilitates replication fork protection and restart, strongly suggests a connection between MMEJ 
and MMBIR mechanisms. Our result that XRCC1 facilitates replication restart fits with previous 
studies identifying roles for the MMEJ factors POLQ, MRE11, and PARP1 in replication restart 
(25,185,186). We propose a model where resection of single-ended DSBs at collapsed forks by 
the MMEJ machinery, scaffolded by XRCC1, exposes MH that is needed for template switching 
to restart replication. 
 
4.3.2 XRCC1 has Diverse Roles in DNA Metabolism in BRCA2-deficient Cells 
 
Our study also helps to explain the sensitivity of BRCA2-deficient cells to depletion of 
XRCC1 (67,153). While it has been postulated (90) that XRCC1 is recruited to sites of 
replication stress to couple excision repair and/or ligation to fork reversal and restart, XRCC1 
interactions with LIG3 and POLβ do not increase after replication stress or BRCA2 knockdown. 
This implies that the scaffolding of fork remodeling/MMEJ factors is the primary role of XRCC1 
during replication stress and the underlying reason for the synthetic lethality of BRCA2 and 
XRCC1. Previous observations that BRCA2 suppresses MMEJ (65) are extended here by 
showing that in BRCA2-deficient cells, XRCC1 complexes preferentially with MMEJ resection 
factors and DNA polymerases. Additionally, the XRCC1 repair complex more efficiently repairs 
DSBs via MMEJ in BRCA2-deficient cells than in WT cells.  
Our observations that XRCC1 is intimately linked with fork degradation and restart in 
BRCA2-deficient cells also support a model where XRCC1 preferentially scaffolds nucleases 
and polymerases in HRD cancers. Identification of specific interactions between POLQ and 






cancer therapy. Direct interactions between protein factors that are both required for and specific 
to MMEJ are potential targets for small molecule inhibitors. Additionally, defining the 
mechanism of POLQ and PARP activity more precisely will inform the applications of these 
inhibitors to BRCA-deficient cancer therapy (57,58). 
4.3.3 A Genomic Cluster of DNA Repair Genes are Underexpressed in BRCA-deficient 
Breast Tumors 
     The close connection of XRCC1 to both PARP1 and BRCA2 may be important in PARPi 
therapy for HRD cancers. PARP inhibition and XRCC1 deficiency have been observed to be 
synthetic lethal in multiple contexts (67,155,174), perhaps because of PARP1 hyperactivation in 
the absence of XRCC1 (7). Our observation that low XRCC1 expression is associated with poor 
survival in breast cancers is supported by previous studies (187). Our finding that XRCC1 
expression is closely correlated with other 19q13.3 genes is surprising, and may be indicative of 
amplifications and/or deletions in that region. Additionally, the cluster of DNA repair genes in 
19q13.3-4 implies that large functional changes in DNA repair capacity may occur as a result of 
regulatory or structural changes to this region of the genome. In fact, copy number variation in 
this region has been reported in several cancers, including breast and ovarian cancers (188-190). 
The underexpression of XRCC1, ERCC1, ERCC2, and PNKP in Signature 3 breast cancers, 
combined with our observation that XRCC1, ERCC1 and PNKP expression impacts breast 
cancer survival, indicate a functional DNA repair change in HRD cancers that affects treatment 
response. Additionally, XRCC1, ERCC1, ERCC2, and PNKP deficiencies have been 
independently implicated in both PARPi and platinum compound sensitivity (174-178), linking 






         The underexpression of XRCC1 in specifically Signature 3 (HR-deficient) breast cancers is 
surprising, based on the abundance of evidence supporting a role for XRCC1 in MMEJ, 
including our own data that XRCC1 activity is suppressed by BRCA2. This is in contrast to the 
overexpression of the MMEJ polymerase POLQ in Signature 3 cancers (24). One possible 
explanation for this observation is that XRCC1 and POLQ act separately in MMEJ variant 
pathways that compete and are differentially mutagenic, and low XRCC1 expression in HR-
deficient cells allows POLQ to repair breaks via a pathway that creates Signature 3 mutations. 
Another explanation is that XRCC1’s role in fork restart and fork stability in conjunction with 
MRE11 promotes genome stability in BRCA2-deficient cells. XRCC1 promotes both fork restart 
and fork degradation in BRCA2-deficient cells, as does MRE11. It is possible that when XRCC1 
is unable to act at stalled and collapsed forks, POLQ/RAD52 pathways can hijack stalled forks, 
as was shown recently for p53/MRE11-defective cancers (186). Supporting both these models is 
evidence that PARP1 is hyperactivated in the absence of XRCC1 and BRCA2 (7,191), which 
may mediate increased recruitment of POLQ to DSBs (26).  
In summary, our identification of an MMEJ-competent protein complex that is 
suppressed by BRCA2 and is activated by replication stress is a mechanistic step forward for our 
understanding of MH-based repair that may be important for HRD cancer therapy. 
Underexpression of a genomic cluster of DNA repair genes is a unique characteristic of HRD 
cancers, and may contribute to the efficacy of PARPi and platinum compounds in these settings. 
Further investigation of the relationship between POLQ, MRE11, PARP1, and XRCC1 should 










5. SUMMARY AND FUTURE DIRECTIONS 
 
Our evidence that IR induces MMEJ is an important result that has since been validated 
by independent studies. The Wellcome Trust Sanger Institute published a paper documenting the 
mutational signatures of second malignancies that arose as a result of IR therapy for a first 
malignancy (192). The found that, relative to IR-naive tumors, IR-associated tumors had a higher 
burden of small deletions, which often had microhomology at the junction (192). Cornforth et al. 
recently found that radiation-induced translocations were mediated by microhomology (193). 
Irradiation using high-LET titanium ions led to misjoining of Cas9-induced DSBs via 
microhomology, which was not observed after low-LET irradiation (194). The Cas9-DSBs were 
induced several days after exposure, indicating a persistent signal that activates MMEJ that is 
dependent on strand break complexity (194). 
Activation of MMEJ by IR has implications for RT, space exploration, and other 
exposures, as this work rationalizes testing of MMEJ inhibitors, including PARPi, CK2i, and 
POLQi in these contexts. High-LET radiation in space and proton therapy environments 
stimulates MMEJ, possibly increasing the efficacy of MMEJ inhibition in these contexts. 
However, the multiple roles of CK2, PARP1, and POLQ in the cell complicate their targeting 
with chemicals, as they may have toxic or carcinogenic outcomes due to their roles in normal 
genome repair and cell signaling. Therefore, a specific MMEJ inhibitor is desired. Our 
identification of an MMEJ-specific interaction in XRCC1-MRE11 raises the possibility of 
targeting their interaction using small molecules to inhibit MMEJ. 
The discovery that XRCC1 plays multiple roles in DNA metabolism in BRCA2-deficient 
cells is surprising. While increased MMEJ activity of the XRCC1 complex in BRCA2-deficient 
cells was anticipated, the strong replication restart and degradation phenotypes of XRCC1 
depletion we observed were not, and suggest a close connection with MRE11 in these tumors. 






unexpected. Further investigation of how MRE11, POLQ, and XRCC1 cooperate (or compete) in 
both MMEJ and replication fork dynamics is necessary. 
The identification of 19p13.3 XRCC1 gene correlates in breast cancer is an exciting 
observation with potential therapeutic implications. However, we are currently working to better 
understand how XRCC1 and these correlates impacts survival. For example, whether sensitivity 
of BRCA-deficient tumors to platinum agents or PARPi is mitigated by overexpression of any of 
these 19p13.3 factors is an important question. Furthermore, it is unclear whether XRCC1 
expression correlates more strongly with survival specifically in BRCA1, BRCA2, or other 
germline HR mutants. Similarly, whether 19p13.3 genes correlate more closely in germline 
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